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Abstract 
The incidence of the idiopathic inflammatory bowel diseases 
ulcerative colitis and Crohns disease appears to have risen 
markedly during the 20th century. These diseases now account for a 
considerable proportion of the workload of gastroenterologists in the 
developed world, and may affect as much as 1% of the population at 
some point in their lives. 
 
The aetiology of these diseases has been subject of much research 
over a number of decades and it is clear that both genetic and 
environmental factors are involved. The certain knowledge of 
environmental risk factors however remains scant. Similarly 
although inflammatory bowel diseases cause considerable morbidity 
and a small amount of mortality for their sufferers directly there is 
little agreement as to their overall impact once indirect effects are 
accounted for. 
 
This thesis contains studies contributing to the knowledge of both 
these areas using routinely or semi-routinely collected data. It 
examines two hypotheses relating to the aetiology of IBD (that risk is 
related to the season of birth, and that it is related to antibiotic use), 
and two areas of the impact of the diseases (overall mortality and 
fracture risk). 
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With regard to aetiology the studies described show no variation in 
the risk of IBD with season of birth. They do show an increase in risk 
associated with the use of antibiotics, but since this is not specific (it 
is seen to occur with other groups of drugs also) it is far from clear 
that the association is causal. With regard to the indirect impact of 
the diseases a significant excess in overall mortality is demonstrated 
which is greater in Crohns disease than in ulcerative colitis, and is 
greatest in relative terms in the young but in absolute terms in the 
elderly. An excess is also shown for hip fractures in those with 
inflammatory bowel diseases, which is only partially explained by 
the use of corticosteroids. 
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Chapter 1. Introduction 
1.1. A brief introduction to idiopathic inflammatory bowel disease. 
1.1.1. Definition 
The idiopathic inflammatory bowel diseases are in general thought 
of as comprising 2 major subtypes, ulcerative colitis and Crohns 
disease. These diseases are defined by their clinical and 
pathological features. Those features have themselves varied 
somewhat over the years to the extent that Crohns name is now 
associated with a chronic transmural inflammation which can affect 
any part of the gut although he originally described with Ginzburg 
and Oppenheimer a disease limited to the ileum 1.  To allow 
uniformity of diagnosis a number of standardised criteria have 
therefore been produced, the best known of which perhaps are 
those of Lennard-Jones 2. To summarize these ulcerative colitis can 
be thought of as a chronic inflammation of the colon with no 
identifiable cause which extends a variable distance continuously 
from the anus. Crohns disease in contrast is a discontinuous 
chronic inflammation of any part of the GI tract, for which no cause 
is identifiable and which is characteristically although not always 
transmural and granulomatous. Despite the availability of such 
criteria the diagnosis of and between these conditions remains 
unclear in many cases. For practical purposes when studying large 
populations whose disease cannot be individually verified I shall 
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therefore use a working definition that UC and Crohns disease are 
the conditions that attract these diagnoses in clinical practice. 
 
1.1.2. Descriptive epidemiology 
It is unclear whether inflammatory bowel diseases have occurred 
throughout human history.  The earliest references to them may be 
as early as 1859 for ulcerative colitis and 1761 for Crohns disease 
3, but even if these sources are accepted as describing the diseases 
we now accord these names they can only set the latest and not the 
earliest possible advent of the diseases. What is rather clearer is 
that inflammatory bowel diseases have become far more commonly 
diagnosed over the last century 4. Based upon recent publications it 
is likely that in the UK the incidence of Crohns disease is about 
8/106 per year and of UC about 14/106 per year with prevalence of 
around 145/106 and 244/106 respectively 5.  These diseases each 
have their peak onset in early adulthood, but can occur at any age, 
and there is some evidence to suggest that the incidence of Crohns 
disease is growing still among children6, 7, which if the incidence has 
stabilised in adults8 may suggest a shift towards a younger age 
distribution. 
1.1.3. Aetiology 
 
The aetiology of inflammatory bowel disease remains largely 
unknown. In recent years much attention has focussed on genetic 
factors due to their well demonstrated familial aggregation (in 
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particular of Crohns disease) first shown in 1963 9, and the 
subsequent demonstration of heritability via twin studies10 and 
genetic linkages first with areas of the genome and more recently 
with specific genes11. Nevertheless, while genetic factors clearly 
play an important role they cannot account for the rise in incidence 
of the disease over the last century4. Many environmental factors 
have been proposed as potential aetiological factors including 
increasing levels of hygiene 12, 13, the oral contraceptive pill 14, non-
steroidal anti-inflammatory drugs 15, 16 and a wide variety of factors 
associated with a western lifestyle 17. Of these smoking18 is the only 
one which is well established to date, but it is not sufficient to 
explain the entire environmental component of the causation of 
Crohns disease10.   
 
 
1.2. The role of micro-organisms in the aetiology of IBD 
1.2.1. Background 
 
One aspect of the environment which is increasingly accepted as 
being associated with the aetiology of Crohn's disease, is the 
intestinal microflora 19. If as is suggested by animal models such as 
the IL-10 deficient mouse 20 , and the emerging evidence regarding 
probiotics 21, inflammatory bowel diseases may depend upon the 
relationship between the gut and its microflora, then anything 
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interfering with this relationship such as antibiotics or delivery by 
caesarean section might contribute to their aetiology. 
1.2.2. The role of season 
 
Prenatal or perinatal environmental exposures have been postulated 
to alter the risk of a number of diseases manifest later in life over 
recent years 22. Such early exposures have also been the subject of 
some study in inflammatory bowel disease (IBD) 23. One 
manifestation of such effects which has been proposed to exist is an 
association between the month of birth and risk of developing IBD 
latter in life 24-26. Such an association has been hyopthesised to 
arise in other diseases for a number of reasons. In childhood 
psychiatric illness in general it has been hypothesised that  an 
excess of psychiatric disorders among the youngest members in a 
school year (those born in the summer in England and Wales) might 
be due to stresses associated with being the youngest in the 
class27. This is likely to be related closely to those factors which 
cause the same group of children to be overrepresented among 
groups with learning difficulties28. Another proposed mechanism 
for a relationship with season of birth is the suggestion that an 
excess of birth defects among those conceived in spring in one area 
of Minnesota might be explained by the use of herbicides applied at 
that time of year29. In the case of Crohns disease however as for 
Coeliac disease, multiple sclerosis, type I diabetes and 
schizophrenia the suggested mechanism is that  the disease is the 
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result of an infection that occurs seasonally24-26, 30-32. In the cases of 
multiple sclerosis and schizophrenia it is suggested that this is via a 
direct neurological effect of Borelliosis30, whereas in Coeliac disease 
the mechanism is suggested to be the induction of an immunological 
cross reaction with Gliadin32. In the case of Crohns disease the 
proponents of a seasonal association have in general not specified 
the mechanism by which they thought an infection might act 
although in at least one study the possibility of persistence of virus 
causing a direct effect upon the gut has been raised25. 
 
Two recent publications, one from the UK 25, and the other from 
Denmark 26 have examined cohorts of Crohns patients for such 
seasonality of birth. The findings of these two studies as well as 
their interpretations differ markedly. The British study was of adult 
patients diagnosed between 1972 to1989 by four regional IBD 
registers in which a weak association was found between Crohns 
disease and birth in the first half of the year. The second (Danish) 
study examined national computerised hospital discharge records of 
children and young people aged less than 20 years coded between 
1977-1992 for Crohns disease. This latter study found an 
apparently stronger association with month of birth with the peak 
risk being for those born during August with a sine-wave variation 
in risk between those born in different months of the year. The 
authors suggest that the differences compared to the British study 
might be explained by differences in age mix and nationality of the 
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subjects, and further suggested that their findings give support to 
the importance of in utero and early childhood events in the 
aetiology of Crohn's disease. 
 
 
1.2.3. The role of antibiotics 
Antibiotics can clearly alter at least temporarily the bacterial 
microflora and are therefore worth considering as a potential risk 
factor for IBD. The first evidence of the possibility that alterations in 
intestinal microflora, occasioned by antibiotics, might contribute to 
the aetiology of Crohn's disease was from two case control studies 
33, 34 which showed an association between increased antibiotic use 
and  diagnosis of Crohn's disease in children. Both studies relied on 
recall of use of antibiotics, assessed many years after the initial 
diagnosis. Such recall of exposures is known to be susceptible to 
bias in studies where the onset of disease could influence recall. In 
both studies the authors consider the finding an artefact, and not 
causal. Demling in 199435 hypothesised on the basis of a subjective 
assessment of the trends in Crohns disease and antibiotic use over 
time that a causal link may exist. Since antibiotic use is common it 
might make a large contribution to the risk of Crohns disease in the 
population if the association these studies have described is causal. 
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1.3. The impact of IBD 
1.3.1. Mortality in IBD 
 
The mortality associated with diseases is studied for a number of 
reasons. Clearly if mortality is high this will render the disease more 
important and hence direct therapeutic and research effort towards 
it. It is therefore important for policy makers to have information 
regarding a diseases mortality. Knowledge of the prognosis of 
diseases is also of immense importance both to people suffering 
from them and to their physicians since patients have an 
understandable wish to know the implications of any diagnosis they 
receive.  Both of these reasons for wishing to know the mortality 
associated with a disease apply to inflammatory bowel diseases. 
One other group also greatly interested in mortality risk are life 
insurance companies who load their premiums (increase them) to 
balance any perceived higher risk associated with having a known 
diagnosis. This has led to criticism of what has been perceived as 
unfair loading of policies for IBD patients36.  
 
At the present time there is considerable uncertainty as to what if 
any increase in mortality is associated with IBD. Current estimates 
range from a 40% decrease to a 70% increase in mortality with 
ulcerative colitis (UC),37, 38 and from no increase to doubling in 
mortality with Crohns disease (CD).39, 40 (Table 1-1, Table 1-2). 
These inconsistencies may be due in part to the selected nature of 
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cases studied, a failure to control for important confounders such as 
smoking and weight, and differences in the time periods studied. To 
address these issues statistically powerful general population based 
studies of contemporary mortality risk in IBD patients are clearly 
required. 
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First author / Year Area Period Cohort Deaths 
Standardised Mortality 
Ratio  (95% CI) 
      
Langholz et al 1992
41
 Copenhagen 1962-1987  1,104  121          107 
Farrokhyar et al 2001
39
 3 English districts in Midlands 1978-1986  356  41  103 (79-140) 
Persson et al 1996
42
 Stockholm  1955 -1984  1,547  255  137 (120-154) 
Ekbom et al 1992
43
 Uppsala, Sweden  1965-1983  2,509  505  140 (120-150) 
Palli et al 1998
37
 Florence 1978-1992  689  47  62 (40-80) 
Davoli et al 1997
44
 Rome 1970-1989  508  27  98 (64-142) 
Viscido et al 2001
45
 Italy 1964-1989  2,066  93  100 (80-120) 
Gyde et al 1982
38
 Birmingham 1940-1976  676  141  170 
 
Table 1-1 Previous large studies of all-cause mortality in UC patients 
 29
First author / Year Area Period Cohort Deaths 
Standardised Mortality 
Ratio  (95% CI) 
      
Cottone et al 199646 Sicily, Italy  1973-1993  531  9  97 (40-180) 
Farrokhyar et al 200139 3 English districts in Midlands 1978-1986  196  23  94 (59-140) 
Persson et al 199642 Stockholm  1955-1984  1,251   151 (129-175) 
Weterman et al 199040 Leiden, Holland 1934-1984  659  64  223 (175-285) 
Ekbom et al 199243 Uppsala, Sweden 1963-1986  1,469  179  160 (140-190) 
Palli et al 199837 Florence 1978-1992  231  23  136 (90-200) 
Jess et al 200247 Copenhagen followed 1967-1987  374  84  130 (101-150) 
Mayberry et al 198048 Cardiff, UK 1930s-1970s  219  40  216 
 
Table 1-2 Previous large studies of all-cause mortality in CD patients 
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1.3.2. Fractures in IBD 
 
Although many studies have shown that IBD patients are at 
increased risk of osteoporosis 49-53 there is relatively little data as to 
the extent of the increased risk of fracture in these patients relative 
to the general population. A small number of case series have 
suggested high levels of osteoporotic fracture54, 55, but data from the 
available controlled studies are inconsistent, with one study showing 
a rise in fracture risk both for UC and Crohns 56, two an increase in 
risk in Crohns but not in UC 57, 58 and one no increase in risk in 
either59. Since corticosteroids are a risk factor for osteoporosis60, 
and are widely used in IBD they might explain the associated 
osteoporosis.  However the size of the contribution from 
corticosteroids is unclear 49, 61-64.  
 
Of the controlled studies of fractures to date only one has addressed 
the role of corticosteroid use 57, and in this study the use of 
corticosteroids was a risk factor for fracture in Crohns disease but 
not in UC.  Important limitations of this study however included the 
use of retrospective data derived from questionnaires, and the ability 
only to examine cumulative duration of steroid use which might 
underestimate the role of these drugs if as has recently been 
suggested their effect is reversible65.
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1.4. Aims and studies 
 
The overall aim of this thesis is to examine factors relating to both 
the aetiology and impact of IBD in those areas of uncertainty 
identified above using available data. Within this wide brief specific 
objectives are addressed by individual studies which are outlined 
below. 
 
1.4.1. Chapter 2 
This chapter examines the possibility that the season in 
which one is born affects the risk of IBD 
 
1.4.2. Chapter 4 
 
This chapter examines the hypothesis that antibiotic use 
might predispose to Crohns disease. 
 
1.4.3. Chapter 6 
This chapter examines all cause mortality rates in IBD 
patients. 
 
1.4.4. Chapter 7 
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This chapter examines the risk of hip fracture in IBD 
patients and its relationship to the use of corticosteroids. 
 
In addition to these studies describing specific studies Chapter 3 
and Chapter 5 give background information on the data used in 
Chapter 1, Chapter 6 and Chapter 7. The final chapter (Chapter 8) 
summarises the findings of the studies, and draws some 
conclusions.
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Chapter 2. Month of birth and the risk of Crohns disease  
2.1. Introduction 
The study presented in this chapter addresses the inconsistencies in 
the methodologies and results between previous examinations of 
the possible association between birth at certain times of the year 
and subsequent diagnosis of IBD. It is not based upon any single 
hypothesis as to the mechanism by which such association might 
occur, but rather examines for any seasonality by whatever 
mechanism it might arise. 
2.2. Methods 
2.2.1. IBD case data used in this study. 
This study utilises data originally collected for a survey of childhood 
Inflammatory Bowel Disease (IBD) in the British Isles by the British 
Paediatric Surveillance Unit (BPSU), and the British Society of 
Gastroenterology Research Unit (BSGRU). This survey as 
published is a record of a 13 month programme of prospective 
reporting of new diagnoses of IBD under age 16 encountered by 
paediatricians, gastroenterologists, surgeons and pathologists who 
were members of the British Society of Gastroenterology (BSG) or 
the Royal College of Paediatrics and Child Health (RCPCH) in the 
UK and the Faculty of Paediatrics of the Royal College of Physicians 
of Ireland. Participating members of these organisations received 
once a month a card on which they were to record whether they had 
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encountered any new diagnoses of IBD under the age of 20 during 
the month. This card was to be returned whether or not there were 
any cases to report. In order to confirm the initial clinical diagnosis 
from the reporter of the case, a follow up questionnaire was sent. 
This allowed confirmation that the initial diagnosis remained valid, 
as well as ascertaining date of birth and of presentation.  From the 
previously published data we removed notifications from the 
Republic of Ireland, and to it we added notifications of patients aged 
16-20 years from the BSGRU survey.  
 
 
2.2.2. Population data used in this study 
The monthly numbers of live births during the period when children 
reported above were born (1978-1998) were obtained for England 
and Wales 66, 67, Scotland (from General Register Office for 
Scotland: personal communication) , and Northern Ireland (from 
Northern Ireland Statistics and Research Agency: personal 
communication). These numbers are given in Appendix 1. From 
them was calculated the number of live births per month from 1978 
to 1998 for the whole of the UK Table 2-1.
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  January February March April May June July August September October November December
1978  54374 51269 58906 55841 58721 57360 58467 58898 60236 60347 55620 56995
1979  60080 55666 64283 61772 65246 62457 64332 61858 60278 62436 58631 57605
1980  62957 59028 64115 64160 66037 62827 66513 62579 63707 64216 57741 59694
1981  61158 55794 63508 60813 62575 61587 64820 62187 61530 61689 57837 57358
1982  59325 55084 62532 60010 61568 58732 62438 61535 61874 61470 57112 58209
1983  59108 54575 61611 60065 62470 62174 63137 62092 62241 59344 57017 57699
1984  58979 55913 60947 57597 61890 61134 64022 63932 63017 63771 60403 57329
1985  62986 56692 63513 61517 65561 61906 66754 65124 64862 64563 59291 57842
1986  61832 56524 63974 63843 66270 63633 65042 64785 64711 64298 58131 61921
1987  62677 57763 65448 64142 67609 67389 68159 65884 66717 65884 60944 63190
1988  65270 62885 69227 65689 68394 66153 68045 67935 67104 63315 61065 62397
1989  63674 59069 66670 64114 68559 66830 67700 66810 64099 64592 62183 62960
1990  64835 59791 66639 64659 69408 68367 70795 69208 67547 68617 65186 63620
1991  67472 61088 65902 64755 68019 66419 70486 68369 67105 67036 62532 63306
1992  66672 62481 66643 65324 66752 66626 69151 66203 66171 64147 60394 60397
1993  62924 57329 64169 62215 64552 65336 66699 65384 66546 64327 59905 62360
1994  63055 57414 65481 62517 65287 64683 64392 62949 63347 62770 59165 59485
1995  61059 56127 62691 58671 64036 63049 63611 62918 62149 62406 58391 57003
1996  61381 56957 59705 57469 60705 60045 64969 63299 63204 64240 60641 60763
1997  62215 55917 60311 61771 62337 60931 63849 61623 60851 60349 56897 59766
1998  60473 54944 60537 59250 59396 60145 63655 61073 62347 60755 56350 57762
 
 
Table 2-1  Numbers of live births by month in the UK 1978-1998
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Statistical analysis 
The expected number of cases for each month was obtained by 
dividing the observed cases born in each year between the year's 
months in the ratio of the total births within the months of that year. 
The monthly expected cases were then summed for each month 
over all 20 years. Total numbers of observed cases by calendar 
month of birth were similarly summed across the 20 year period. 
The numbers of cases expected were then compared to the number 
observed using a Chi-Square test. This was repeated examining for 
six-month periods (January to June and July to December) instead 
of months. (The same division of the months which demonstrated a 
weak association between birth in the first half of the year and 
subsequent Crohns disease in the study by Haslam and colleagues 
25.) 
 
The monthly observed risk of births joining this incident cohort was 
calculated as the proportion of those born in a given calendar month 
between 1978 and 1998 diagnosed with IBD in the study period per 
100,000. Expected risks were calculated both as a constant rate 
model across the calendar months, and as a periodic model. 
 
In the constant risk model, risk was calculated as the proportion of 
all births between 1978 and 1998 that were diagnosed with IBD 
during the study period also per 100,000. 
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For periodic regression models methodology similar to that 
previously used to show a suggested link between the season of 
birth and risk of IBD 26 was used. I.e. linear regression models 
incorporating as covariates in a linear regression, sine and cosine 
terms were used to model the relationship between risk and month, 
and also between observed and expected numbers of cases by 
month. 
 
These constant rate and periodic models were then compared and 
likelihood ratio tests were used to assess whether the inclusion of 
the periodic term significantly improved the fit of the model.  
 
The equations of the models used were  
 
Risk = const. x Ǻ1sine(month 30 Pi/180) x ȕ2cos(month 30 Pi/180) 
(For modelling risk with a periodic component.) 
 
Risk = const.   
(For modelling risk without a periodic component.) 
 
 
N observed = const. x ȕ 1 N expected x ȕ 3sine(month 30 Pi/180) x  
ȕ4cos(month 30 Pi/180) 
(For modelling numbers of diagnoses with a periodic component.) 
 
N observed = const. x ȕ1 N expected  
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(For modelling numbers of diagnoses without a periodic component.) 
 
 
Since a single sine cosine pair constrains the model to have only 
one maximum and one minimum within the year, models were 
refitted with 2 and then 3 sine cosine pairs to permit a closer fit 
between model and data. Again the contribution of the periodic 
element of the models was assessed using likelihood ratio tests.  
 
Analyses were repeated for all IBD cases, and for both UC and CD 
separately.  
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2.3. Results  
2.3.1. Description of cases observed. 
In total there were 1040 incident cases of IBD diagnosed in those 
aged 0-20 years in the UK during the study period of June 1998 to 
June 1999. There were 634 cases of Crohn's disease (CD), 277 
cases of ulcerative colitis (UC), 12 cases of Orofacial 
Granulomatosis (OG), and 117 cases of indeterminate colitis (IC) 
Table 2-2. The median year of birth of these cases was 1984 with a 
mode in 1983. The interquartile range ran from 1982 to1987. 
Diagnoses for each month of birth during the years 1978-1998 are 
given in Table 2-3. 
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 Month of birth 
IBD type 
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Crohns Disease 69 45 44 59 49 58 59 56 61 43 52 39 634
Indeterminate Colitis 6 9 12 12 10 13 8 9 8 12 9 9 117
Orofacial Granulomatosis 2 1 1    1 2  1 1 3 12 
Ulcerative Colitis 26 26 23 17 29 20 20 25 20 24 20 27 277
              
Total 103 81 80 88 88 91 88 92 89 80 82 78 1040
 
Table 2-2 Counts of IBD diagnoses by calendar month of birth and IBD type
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1978 1  1 1 1 1 2 2 9
1979 3 3 1 4 2 2 2 1 2 4 4 4 32
1980 2 5 5 5 4 4 5 5 6 7 7 3 58
1981 7 6 8 8 10 8 10 6 11 5 5 8 92
1982 12 2 10 5 8 11 11 13 8 6 12 15 113
1983 12 11 6 11 13 11 10 14 14 7 13 7 129
1984 12 14 7 9 7 12 12 10 5 8 8 9 113
1985 12 7 11 14 14 9 8 9 6 7 4 5 106
1986 12 7 7 7 7 10 7 7 9 8 6 6 93
1987 7 5 6 8 4 9 4 10 5 8 6 5 77
1988 6 7 9 7 6 4 7 5 5 2 4 3 65
1989 5 3 3 6 5 3 4 5 5 2 5 5 51
1990 4 3 3 1 1 2 2 2 3 2 2 25
1991  2 1 2 2 2 2 4 2 17
1992 1 3 1 2 1 3 1 2 3 2 19
1993 2 2 1 1 1 1 1 1 2 12
1994   1 2 2 2 7
1995 2 1 1 1 1 1 1 8
1996 2  1 1 1 2 1 8
1997 1  1 1  1 4
1998    2 2
 103 81 80 88 88 91 88 92 89 80 82 78 1040
Table 2-3 IBD cases born by month 1978-1999. (The number given is the total of  Crohn's disease (CD), ulcerative colitis (UC), 
Orofacial Granulomatosis (OG), and indeterminate colitis (IC))
 42
2.3.2. Observed and expected numbers of IBD diagnoses compared 
using the Chi squared test. 
 
Calculated numbers of observed and expected diagnoses of IBD, 
CD and UC by calendar month are given in Table 2-4. 
 
There was no statistically significant difference between the 
observed and expected numbers for IBD (P = 0.88 by chi squared 
test), CD (P = 0.17) or UC (P = 0.77). These differences remained 
non-significant when the data were analysed by half year (January 
to June and July to December) as opposed to month (P = 0.40 for 
IBD, P = 0.50 for CD and P = 0.70 for UC). 
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Jan Feb Mar Apr May June July Aug Sept Oct Nov Dec 
             
CD observed 69 45 44 59 49 58 59 56 61 43 52 39 
CD expected 52.11 48.22 54.01 52.30 54.74 53.29 55.40 54.27 54.02 53.51 50.08 50.37
             
UC observed 26 26 23 17 29 20 20 25 20 24 20 27 
 UC expected 22.78 21.07 23.56 22.83 23.91 23.28 24.21 23.69 23.61 23.41 21.87 22.03
             
IBD observed 103 81 80 88 88 91 88 92 89 80 82 78 
IBD expected 85.49 79.13 88.56 85.76 89.79 87.42 90.88 89.00 88.61 87.80 82.13 82.67
 
Table 2-4 Observed and expected numbers of diagnoses of IBD by calendar month. CD Crohns disease, UC ulcerative colitis, IBD 
the total CD, UC, Orofacial Granulomatosis (OG), and indeterminate colitis (IC)) 
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2.3.3. Observed and expected risks of IBD diagnoses compared 
using the Chi squared test. 
 
 
Table 2-5 shows the monthly observed risk of IBD diagnosis during 
the study period for UK live born infants from 1978-98. Also shown 
is the risk that would be expected if risk were constant throughout 
the year irrespective of calendar month of birth. The application of a 
chi squared test to these figures shows no significant difference 
between observed and expected rates (P =1.00 each of all IBD, UC 
and CD. 
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 Jan Feb Mar Apr May June July Aug Sept Oct Nov Dec 
UK births 1978-98 1,303 1,202 1,337 1,296 1,355 1,328 1,377 1,345 1,340 1,331 1,245 1,258
No. CD diagnoses 69 45 44 59 49 58 59 56 61 43 52 39 
Observed Risk CD 5.30 3.74 3.29 4.55 3.62 4.37 4.28 4.16 4.55 3.23 4.18 3.10
Expected Risk CD 4.03 4.03 4.03 4.03 4.03 4.03 4.03 4.03 4.03 4.03 4.03 4.03
No. UC diagnoses 26 26 23 17 29 20 20 25 20 24 20 27 
Observed Risk UC 2.00 2.16 1.72 1.31 2.14 1.51 1.45 1.86 1.49 1.80 1.61 2.15
Expected Risk UC 1.77 1.77 1.77 1.77 1.77 1.77 1.77 1.77 1.77 1.77 1.77 1.77
No. IBD diagnoses 103 81 80 88 88 91 88 92 89 80 82 78 
Observed Risk IBD 7.91 6.74 5.98 6.79 6.49 6.85 6.39 6.84 6.64 6.01 6.58 6.20
Expected Risk IBD 6.62 6.62 6.62 6.62 6.62 6.62 6.62 6.62 6.62 6.62 6.62 6.62
 
Table 2-5 Observed and expected risks of diagnosis of IBD during the study period among UK births from 1978-98. CD Crohns 
disease, UC ulcerative colitis, IBD the total CD, UC, Orofacial Granulomatosis (OG), and indeterminate colitis (IC)) 
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2.3.4. Periodic models of risk with one sine cosine pair. 
The fitted periodic models of risk using models with one sine cosine 
pair are shown in figures Figure 2-1 for ulcerative colitis, Figure 2-2 
for Crohns disease and Figure 2-3 for all IBD.  Also plotted are the 
observed levels of risk and a model assuming constant risk across 
the twelve months of birth. 
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Figure 2-1 Models of risk for Ulcerative colitis. 
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Models of CD risk
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Figure 2-2 Models of risk for Crohns disease. 
 
Models of risk for all IBD
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Figure 2-3 Models of risk for all IBD (the total of CD, UC, Orofacial 
Granulomatosis (OG), and indeterminate colitis (IC) cases).
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A comparison between these periodic models and constant risk 
models using a likelihood ratio test showed that any improvement in 
fit as a result of the inclusion of periodic terms was not significant (P 
= 0.84 for all IBD, P = 0.87 for CD and P = 0.18 for UC). 
 
2.3.5. Periodic modelling of expected numbers of cases with one 
sine cosine pair. 
Similarly comparing models examining the relationship between 
observed and expected numbers, the likelihood ratio test showed 
that models incorporating periodic terms did not fit significantly 
better than those without (P = 0.95 for all IBD, P = 0.90 for CD and 
P = 0.42 for UC). 
 
2.3.6. Periodic modelling of risk with more than one sine cosine pair. 
Models with two and three sine cosine pairs showed a visibly better 
fit (Figure 2-4, Figure 2-5, Figure 2-6, Figure 2-7, Figure 2-8, Figure 
2-9), but none of them were significantly better than the non-periodic 
model when taking the increase in model saturation into account.
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Figure 2-4 Models of risk of all IBD using 2 sine cosine pairs 
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Figure 2-5 Models of risk of UC using 2 sine cosine pairs 
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Figure 2-6 Models of risk of CD using 2 sine cosine pairs 
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Figure 2-7 Models of risk of all IBD using 3 sine cosine pairs 
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Figure 2-8 Models of risk of CD using 3 sine cosine pairs 
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Figure 2-9 Models of risk of UC using 3 sine cosine pairs
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2.4. Discussion 
2.4.1. Findings 
This study found no statistically significant relationship between 
month of birth and the risk of developing inflammatory bowel 
diseases in the early years of life. This remained true whether the 
relationship was examined using a chi squared test or periodic 
regression. In the case of chi squared testing this was true both 
comparing between months and between the halves of the year. 
Similarly for periodic modelling the addition of further periodic 
components did not reveal any relationship. 
 
2.4.2. Comparison with other studies 
These findings are consistent with the previous British study of older 
Crohns disease patients 25 but are at odds with the published 
interpretation of a series of cases of similar age from Denmark 26. 
The similarity in the age structure between our study and the recent 
Danish one demonstrate that age cannot explain the difference 
between these and the Danish findings (as was suggested by the 
authors of this study as a possible explanation of the difference 
between their findings and previous studies). There are however 
differences between the studies which may explain the difference in 
findings. These differences include methods of case ascertainment, 
time-period of case diagnosis and statistical technique. The 
ascertainment of cases in the data used for this study is without 
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doubt incomplete. It is however extremely unlikely that this has in 
any way biased our results since to do so it would be necessary for 
the probability of ascertainment to be related to the calendar month 
of birth. Similarly although the data used here relate only to 
diagnoses in one 13 month period (compared to all from 1957 to 
1992 in the Danish study), it seems unlikely that seasonality of this 
nature occurred until but not after the early 1990s. Finally with 
respect to statistical technique, although we have used methodology 
similar to that previously described one important difference is that 
we have quoted a significance test for the periodic regression 
models.  
 
2.4.3. Limitations of this study 
One major problem of methodology in all of the studies of this issue 
to date that we have been unable to overcome is the necessity of 
summing observed births within a calendar period over the years. 
Although this is necessary to obtain enough births in each month for 
a reasonably stable estimate, it imposes a limit of 12 data points that 
ensures that statistical models unless they are kept parsimonious 
will become rapidly saturated. This may explain the apparently good 
fit that can be seen from graphical representations of models for 
which periodic components give no significant benefit. For this 
reason unless any true periodicity had a form which approximated 
fairly well to a sine wave it might be hard to detect by this 
methodology. However to overcome this problem a truly massive 
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study examining the incidence in a huge population over many 
years would be necessary (to allow each separate month of 
chronological time to be counted as an independent period within 
the analysis), and such a study is at present not feasible. In fact 
given that seasonal factors may vary to some extent geographically 
it may never be feasible. 
 
With respect to this study specifically there are some limitations to 
the data used. Although the birth, data being derived from national 
statistics are likely to be highly valid, the data on IBD diagnoses are 
perhaps less reliable in two respects. Firstly it is possible that some 
of the IBD cases notified did not have IBD. This possibility was 
guarded against by rechecking the clinicians opinion of the 
diagnosis by questionnaire. Nonetheless it is possible that there was 
some error in the diagnosis. Since such error is unlikely to have 
been differential between months of birth its only effect would be to 
slightly reduce the power of the study (i.e. to impart a null bias). 
Secondly since return of reporting cards for the surveillance was 
incomplete it is possible that some cases were not reported. One 
indication perhaps of this under reporting is the age distribution of 
our cases. As can be seen in Table 2-3 the numbers of cases born 
in the late 1990s is low which one would expect since these children 
would have been young at the time of data collection and Crohns 
disease is very rare in young children. What one would not expect is 
the fall off in numbers diagnosed with birth before 1983 since the 
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incidence would be expected to be higher among 20 year olds than 
16 year olds. It is likely that this reflects poorer levels of response 
and of reporting among adult physicians (who would be likely to care 
for these older groups) than among Paediatricians. It is unlikely 
however that such non-reporting varied in a manner related to 
month of birth, and hence this should not affect the validity of the 
results. A further potential cause for concern is the apparent excess 
of births in January among cases in this study. This might lead one 
to question whether some subjects with unknown date of birth have 
been assigned the 1st of January of their year of birth. In fact this is 
not the case since a specific date of birth was obtained for each 
case, and inspection of the data confirms that cases were born 
throughout January without undue numbers concentrated on the first 
of the month. It is likely therefore that this is a chance finding which 
would be in line with the lack of significant variation from a constant 
risk of IBD across the months of the year which we have shown. 
2.4.4. Conclusions 
Although the lack of evidence of any variation in risk of Crohns 
disease by month of birth in this or previous studies does not prove 
that no such variation exists, it seems unlikely that future studies in 
the UK at least will find such evidence. This does not by any means 
exclude the possibility that factors acting specifically at or around 
the time of birth may be important in the aetiology of this disease, 
but it does suggest that such aetiological factors may be unlikely to 
be found among exposures varying by season. 
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Chapter 3. The General Practice Research Database 
3.1. Introduction 
This chapter will first give a brief description of the General Practice 
Research Database (GPRD). It will then describe the subsets of this 
database used in the studies presented subsequently. 
 
3.2. The nature of the GPRD 
The General Practice Research Database (GPRD) is a collection of 
anonymous computerised patient records from over 500 British 
general practices. It is the worlds largest longitudinal, primary care 
database and contains approximately 50 million patient years of 
data. Collection began in 1987 as a commercial enterprise by VAMP 
(Value Added Medical Products), the ownership and running of the 
database subsequently passed to Reuters who in turn gave it to the 
Department of Health of the UK government68.  
 
Throughout these changes in ownership and management the 
GPRDs data collection has remained uniform. Data are downloaded 
periodically from practice computer systems that were initially 
uniform, but subsequently have varied. The data collected has 
remained constant, and is reformatted from differing practice 
computer systems for uniform presentation. To ensure data quality, 
contributing practices receive data quality training, and are audited 
to ensure that at least 95% of prescribing and morbidity events are 
 57
included69. Practices are considered to contribute data which is up 
to standard when this as well as a variety of other criteria are met 
and for this reason studies are in general based upon such up to 
standard data70. 
 
3.3. Data collected 
Data collected by GPRD are presented in four basic tables. These 
are: 
 
x The patient records table.  
This contains on one line per subject a practice identifier, a patient 
identifier, date of birth, sex, the dates during which the patient 
contributed up to standard data and information on the registration 
status of the patient with the practice (permanent, temporary, dead 
etc.). 
 
x The medical records table. 
This contains on many lines per subject, practice and patient 
identifiers to precisely identify the subject as well as the date of the 
recorded event, a code identifying what event is being recorded and 
codes showing where the consultation took place and what follow up 
or referral was organised if any. The coding of events utilises a 
modification of the Oxford Medical Information System (OXMIS) 
classification as well as the Read codes so that a very wide variety 
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of signs, symptoms, risk factors, diagnoses and medical 
interventions can be identified. 
 
x The therapy table 
This contains on many lines per subject data detailing the date and 
nature of prescriptions. These are coded using a coded drug 
dictionary based on the Prescription Pricing Authority's dictionary. In 
addition fields are available for the entry of data on the quantity 
prescribed and the duration over which it is to be taken. (These last 
data are far from complete.) 
 
x The prevention table 
This contains on many lines per subject data detailing findings and 
activities related to disease prevention. This includes vaccinations 
and also records of height, weight, blood pressure, allergies and 
smoking and drinking behaviour.  
 
The format of these tables is given in full in Appendix II 
3.4. Strengths and weaknesses of the GPRD. 
(With specific reference to epidemiological studies of IBD.) 
 
The GPRD is a remarkable resource for epidemiology with a 
number of important strengths, but as with any data source it has 
limitations. The following paragraphs will address some of these 
strengths and weaknesses, and their consideration to some extent 
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underpins the design of the studies presented in the following 
chapters. 
3.4.1. Size 
For studies of IBD one of the greatest strengths of GPRD is its size.  
As shown in Table 1-1 the relative rarity of these conditions has led 
to large numbers of small studies and rather fewer large ones. Small 
studies have been adequate to make some progress in the study of 
IBD but they will inevitably provide less precision and less power 
than can be achieved using GPRD when it contains the necessary 
data. 
 
3.4.2. Representativeness. 
Although the practices in GPRD are self-selected they are from a 
wide variety of different areas of the UK, and have been shown to 
have levels of morbidity that mirror national estimates 68. It is 
therefore reasonable to generalise results form the GPRD to the 
population of the UK as a whole. 
 
3.4.3. Prospectively gathered. 
The identification of each subjects entry date to the dataset ensures 
that it is easy to ascertain which data are prospectively, and which 
retrospectively recorded. This is of particular importance for studies 
where exposure recall may be likely to be biased. Perhaps the best 
example of such an exposure and the GPRDs strength in this 
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respect is the use of medication. Since almost all prescriptions in 
GPRD practices are electronically produced and added to the 
database by the same process that produces them, there is very 
little opportunity for error in recording, and almost none for bias. 
 
3.4.4. Contemporary 
Although it seems likely that the aetiology of IBDs (assuming that 
they are distinct entities rather than a final common pathway for a 
large number of disease processes) remains essentially unchanged 
over decades, the same may not be true of their outcome. There is 
good reason to think that the mortality directly attributable to IBD at 
least in the USA and UK may have changed over the years71. Since 
corticosteroids, amminosalicylates and immunomodulators (the 
mainstays of medical therapy for IBD) have all been introduced or 
more widely adopted over a relatively small number of decades it is 
quite likely that other measures of outcome will also have altered as 
a result. Hence the fact that GPRD can provide many thousands of 
patient years of recent data encourages the belief that any results 
should be generalisable to current rather than historical clinical 
settings. 
3.4.5. Validatable 
Although as outlined above strict data standards are maintained for 
the GPRD it is of great importance that systems also exist for the 
independent validation of the data by third parties. The mechanism 
 61
for this is via the requesting of anonymised copies of paper records, 
or the completion of questionnaires by GPs. This system although it 
is sufficiently expensive (£100-200 approximately per validated 
subject) to prevent its application to very large numbers does permit 
validation of samples. By this means a number of diagnoses and 
outcomes have been validated in GPRD 70, 72-76and IBD is one of 
these. In a study of the validity of diagnoses of IBD within the GPRD 
77 92% of diagnoses recorded found to be accurate (the diagnoses 
of Crohns disease (94% accurate) and UC (93% accurate) were 
noted to be more reliable than those for indeterminate IBD (80% 
accurate)). 
 
3.4.6. Short duration of follow-up 
The flip side of having contemporary data is that since there are no 
prospective records prior to 1987, no subject can have very 
prolonged follow up. In fact the situation is somewhat weaker even 
than this would suggest since the turnover of participating practices 
in addition to the mobility of the UK population has ensured that 
many subjects have even less follow up. This means that the power 
available for the following of incident case series is greatly limited. 
 
3.4.7. Incomplete recording 
One problem with the use of any routinely collected data (which is in 
effect what GPRD is) is that what is recorded is determined not by 
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the needs of the research, but by what is felt relevant to the primary 
purpose of the data recording.  This means that recording is 
determined by the GPs assessment of what is relevant to the 
ongoing primary medical care of subjects.  Hence not only is data 
incomplete, but it is likely that there is bias as to which data are 
missing.  For example it is likely that a GP will record that a patient 
drinks heavily if they know this as it may adversely affect health, it 
perhaps less likely that they would record the knowledge that the 
patient was teetotal unless they suffered from a condition which 
might be attributable to alcohol. 
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Chapter 4. Antibiotic use and the risk of Crohns disease. 
4.1. Introduction 
This chapter presents a study carried out in order to examine the 
hypothesis that antibiotic use is associated with the subsequent 
development of Crohn's disease without the potential for recall bias.  
 
4.2. Methods 
4.2.1. Subjects 
All data used in this study were derived from a subset of the GPRD 
prepared for a different study (funded by the Department of the 
Environment, Transport and the Regions  to investigate a possible 
relationship between exposure to Mycobacterium paratuberculosis 
via drinking water and Crohns disease).   
 
The subset contained data from all subjects for whom a new 
diagnosis of Crohns disease was recorded whilst they were 
contributing up to standard data to the GPRD. In addition, for each 
case two individually age and sex matched controls with no previous 
diagnosis of Crohns disease or ulcerative colitis, were available. 
 
Cases with five or more years of prospectively gathered data prior to 
first diagnosis of Crohns disease were extracted. Cases for whom a 
diagnosis of ulcerative colitis had also been recorded were 
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discarded. The controls used here were a randomly selected sample 
of the full set of the controls who also had over five years of 
prospectively gathered data.  
 
4.2.2. Overview of Exposures 
Information on exposures extracted from the GPRD included age at 
index date (grouped in 20 year age bands), gender, smoking 
(classified as current smoking, non-smoking or unknown based 
upon the last relevant record in the dataset prior to the index date), 
and all drugs prescribed, and reason for consultations (usually a 
symptom or diagnosis) and the dates on which these occurred.   
  
4.2.3. Symptoms 
All events recorded as gastrointestinal (GI) infections, perianal 
sepsis, anaemia, irritable bowel syndrome (IBS), abdominal pain or 
diarrhoea were identified among cases using a combination of 
Oxmis and Read codes78, 79 (Table IV-1Table IV-2Table IV-3Table 
IV-4Table IV-5). These are referred to hereafter as GI events. Each 
of these events was assigned to the six-month period in which it 
occurred working back from an index date which was the date of 
Crohns disease diagnosis for cases and the date of the end of data 
for controls. (i.e. events were coded as occurring in the 1st, 2nd, 3rd --
-- nth six-month period prior to the index date.) In order to assess 
whether symptoms were consistent with undiagnosed Crohns 
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disease, the number of GI events for each subject during each six-
month block was plotted (Figure 4-1). The figure shows an excess of 
events consistent with undiagnosed Crohns disease among cases 
which was most marked in the last two years prior to diagnosis. 
Based on this finding we limited our primary analyses of antibiotic 
exposure to the period from the third to the fifth year prior to index 
date, to reduce the possibility that the antibiotic exposure followed 
the onset of any symptom or illness due to Crohns disease. To 
further assess the possibility that any association between 
antibiotics and Crohns disease might be due to prescriptions for the 
symptoms of undiagnosed Crohns disease (i.e., of reverse 
causality) we divided cases and controls according to whether, 
during the studied period (the third to fifth year prior to diagnosis), 
they had any record of  GI  events, or had any drugs for GI disease 
prescribed (GI drugs).  
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Figure 4-1 Symptoms consistent with undiagnosed Crohns disease recorded before the index date. 
The proportion of cases and controls with these symptoms is shown within 6 month periods prior to the index date.
 67
4.2.4. Drugs 
Drugs prescribed were classified according to sections of the British 
National Formulary (BNF), which groups drugs by indication and by 
pharmacological types. For example drugs used for infections are in 
chapter 5, antibacterials in section 5.1 and Penicillins in section 
5.1.1. Prescriptions were assigned to six-month periods as 
described for symptoms and diagnoses above. In this way we 
counted the prescription of antibiotics both in total and in subgroups 
defined based upon the subheadings in BNF section 5.1. We also 
counted all prescriptions, prescriptions of drugs for gastrointestinal 
disease (BNF chapter 1) as GI drugs, oral contraceptive pills (BNF 
section 7.3.1 and 7.3.2)(previously described as associated with 
Crohns disease80, 81),  drugs used for cardiovascular disease (BNF 
chapter 2), and drugs for disorders of the central nervous system 
(BNF chapter 4) (as control drugs, not expected to be associated 
with Crohns). 
 
4.2.5. Analyses 
All analyses were conducted using Stata 7. We calculated odds 
ratios (OR) for developing Crohns disease according to our main 
suspected exposure, usage of antibiotics 2 to 5 years before 
diagnosis, and other exposures. Logistic regression was used to 
assess exposures and to control for potential confounders, i.e. age, 
sex, and smoking. To correct for the effect of an individuals 
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tendency to receive prescriptions in general (rather than those 
specifically for antibiotics) we included within the regression 
analyses a measure of the prescription of other drugs, as the total 
number of prescriptions minus the number for antibiotics. This was 
coded into quartiles.  These analyses were repeated for cases with 
GI symptoms and prescriptions in the 2 to 5 years before diagnosis 
(indicating possible undiagnosed Crohns disease), and those 
subjects with no symptoms or GI drugs during that period. 
Additionally, separate estimates were made for different groups of 
antibiotics, and for the effect of receiving different numbers of 
antibiotics prescriptions.  To assess whether any association was 
specific to antibiotics as opposed to other drug groups we repeated 
our analyses for oral contraceptive pills, drugs used for 
cardiovascular disease, and drugs for disorders of the central 
nervous system. Finally to assess the potential importance of any 
association found if it were causal we calculated the population 
attributable fraction (PAF) using appropriate methodology for 
multivariate analyses82. 
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4.3. Results 
4.3.1. Univariate analyses. 
A total of 587 cases of Crohns disease and 1460 controls were 
available for analysis. Cases had a median of 8.1 years of data 
available (range 5.1-11.6) of which 6.4 years (range 5.0-10.5) 
occurred before diagnosis. Controls had a median of 8.2 years of 
data (range 5.0-11.6). Cases and controls were of similar sex 
distribution (43% male for cases and 44% for controls), but cases 
were slightly older having a mean age at the index date 2.5 years 
greater than that of controls Table 4-1. A greater proportion of cases 
were recorded as being current smokers (28% versus 20%). 
Antibiotics were prescribed on at least one occasion between 2 and 
5 years before the index date for 71% of cases and 58% of controls 
(P<0.001), and cases received on average a greater total number of 
antibiotic prescriptions (median 2 compared to 1 for controls).  
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Table 4-1 Age, gender, antibiotic use, date of entry to study and 
smoking in cases and controls.  
 Case Control  
 N = 587 N =1460  
            n (%)  n (%)  
Age    
   0-20  79 (13)  76 (5) 
   20-40  207 (35)  569 (39) 
   40-60  156 (27)  445 (30) 
   60-80  145 (25)  370 (25) 
P<0.001 
   Median 41.64 43.76 P=0.003 
    
Sex    
   Male  253 (43)  642 (44) 
   Female  334 (57)  818 (56) 
P=0.7 
    
Entry to study    
   Median 1/10/90 1/03/90 P<0.001 
   Range 1/06/87-23/08/93 1/06/87-8/10/93  
    
Smoking    
   Smoker  165 (28)  297 (20) 
   Non-smoker  291 (50)  796 (55) 
   Unknown  131 (22)  367 (25) 
P=0.001 
    
Antibiotic courses *    
   At least one            418  (71)            843  (58) P<0.001 
   Median            2            1 P<0.001 
 
(P values derived by chi squared tests for categorical variables and 
by the Kruskal-Wallis Test for comparison of continuous variables.)
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4.3.2. Multivariate analysis of the role of antibiotics 
In the multiple logistic regression analysis of all cases, there were 
statistically significant associations between Crohns disease and 
prescription of antibiotics 2 to 5 years before the index date (OR 
1.32, 95%CI 1.05-1.65), other drugs (OR 1.54, 95% CI 1.38-1.70) 
and smoking (OR 1.55, 95%CI 1.22-1.98 compared to non-smokers) 
after adjusting for age and gender Table 4-2. Although gender and 
smoking were included in this model on an a-priori basis they did not 
appreciably confound the relationship between antibiotics and 
Crohns disease (their omission from the model leaving the odds 
ratio for antibiotic use unchanged at 1.32).  Restricting the analysis 
to the cases with no symptoms or GI drugs, suggestive of 
undiagnosed Crohns disease between 2 and 5 years before 
diagnosis (252 cases and 1022 controls), the association with 
antibiotic prescriptions was slightly stronger (OR 1.53, 95%CI 1.12-
2.07), and was weaker with other drugs prescribed (OR 1.19, 95%CI 
1.03-1.08).  Repetition of the analysis limited only to those coded as 
current smokers gave a slightly greater estimate of the effect of 
antibiotics. The confidence intervals for this estimate was wide 
however.
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 Table 4-2 Multivariate logistic regression models1 of the association 
between antibiotic use and subsequent diagnosis of Crohns 
disease.  
 Odds Ratio 95% CI 
     
All subjects 
Smoker 1.55 1.22 to 1.98 
Smoking status unknown 0.86 0.64 to 1.16 
Drugs other than antibiotics2 1.54 1.38 to 1.70 
Antibiotics3 1.32 1.05 to 1.65 
     
Subjects without symptoms or GI drugs in 3rd to 5th yrs pre diagnosis 
Smoker 1.55 1.08 to 2.20 
Smoking status unknown 0.79 0.52 to 1.18 
Drugs other than antibiotics 1.19 1.03 to 1.38 
Antibiotics 1.53 1.12 to 2.07 
     
Analysis limited to current smokers only 
Drugs other than antibiotics2 1.48 1.21 to 1.81 
Antibiotics3 1.70 1.08 to 2.70 
    
1All models include age and sex as co-factors in addition to those 
listed.  
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2Drugs other than antibiotics represents prescriptions for all other 
drugs with the exception of antibiotics, and the odds ratio is for 
moving from one quartile of prescription density to the next.  
3For antibiotics the odds ratio is for a comparison of any prescription 
for that group against none. 
 74
4.3.3. Examination of specificity between antibiotic groups 
Examination of the associations between Crohns and different 
groups of antibiotics and with differing levels of exposure gave odds 
ratios ranging between 0.95 and 1.71 (Table 4-3). For two groups 
the odds ratio was significantly greater than one (tetracyclines (OR 
1.33, 95%CI 1.01-1.77) and metronidazole and tinidazole (OR 1.71, 
95%CI 1.05-2.76)). Restriction of the analysis to subjects who had 
had no symptoms suggestive of undiagnosed Crohns disease and 
no prescriptions for GI drugs recorded between 2 and 5 years 
before the index date rendered the association with metronidazole 
and tinidazole non-significant (OR 1.08, 95%CI 0.39-2.99), although 
the association with tetracycline strengthened (Table 4-4). 
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Number exposed (%) Group 
Cases  = 587 Controls = 1460 
OR 95% CI 
       
Ben pen, penicillinase resistant pens 128 (22) 286 (20) 0.94 0.74 to 1.21 
Broad spectrum and anti pseudomonal penicillins 271 (46) 531 (36) 1.10 0.90 to 1.36 
Cephalosporins 91 (16) 153 (10) 1.18 0.88 to 1.58 
Tetracyclines 98 (17) 172 (12) 1.34 1.01 to 1.77 
Macrolides 87 (15) 188 (13) 0.96 0.72 to 1.27 
Sulphonamides and Trimethoprim 87 (15) 160 (11) 1.16 0.86 to 1.57 
Metronidazole and tinidazole 33 (6) 45 (3) 1.70 1.05 to 2.75 
Quinolones 31 (5) 55 (4) 1.15 0.72 to 1.83 
Others 8 (1) 17 (1) 1.09 0.46 to 2.57 
 
Table 4-3 The effect of different groups of antibiotics in all subjects. 
(All ORs are corrected for age, sex, smoking and prescriptions of all non-antibacterial drugs) 
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Number exposed Group 
Cases =252 Controls= 1022 
OR 95% CI 
       
Ben pen, penicillinase resistant pens 47 (19) 169 (17) 0.93 0.64 to 1.36 
Broad spectrum and anti pseudomonal penicillins 96 (38) 317 (31) 1.04 0.77 to 1.42 
Cephalosporins 29 (12) 78 (8) 1.30 0.81 to 2.09 
Tetracyclines 36 (14) 91 (9) 1.72 1.12 to 2.64 
Macrolides 32 (13) 95 (9) 1.12 0.71 to 1.75 
Sulphonamides and Trimethoprim 21 (8) 68 (7) 1.21 0.71 to 2.05 
Metronidazole and tinidazole 5 (2) 19 (2) 1.08 0.39 to 2.99 
Quinolones 4 (2) 19 (2) 0.67 0.22 to 2.03 
Others 2 (1) 5 (0) 1.66 0.31 to 8.76 
Table 4-4 The effect of different groups of antibiotics in subjects with no symptoms or GI drugs. 
(Symptoms suggestive of undiagnosed Crohns disease or prescriptions for GI drugs between 2 and 5 years before the index date.) 
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4.3.4. Examination for a dose response relationship 
There was also no evidence of a dose response relationship 
between frequency of any antibiotic prescription and Crohns 
disease, with similar ORs for 1, 2 to 5, or more than 5 courses 
between 2 and 5 years prior to the index date (Table 4-5). 
 
 
 
Number exposed 
 
Number 
courses
Cases 
(N=252)
Controls 
(N=1022)
OR 95% CI 
 1 62 192 1.57 1.07 to 2.29
All 
antibiotics 
2 to 5 81 258 1.50 1.05 to 2.14
 Over 5 20 50 1.51 0.82 to 2.78
 
Table 4-5 Adjusted odds ratios for the relationships between 
different numbers of courses of antibiotics and Crohns disease in 
subjects with no symptoms or GI drugs.
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4.3.5. Examination of specificity to antibiotics. 
When our analysis was repeated to examine drug groups other than 
antibiotics, we found similar associations between other drugs and 
Crohns disease (Table 4-6). Among all cases the odds ratios of 
1.34 (1.08-1.66), 1.25 (0.95-1.66) and 1.48 (1.00-2.17) were found 
respectively for neurological drugs, cardiovascular drugs and oral 
contraceptives in multivariate analyses analogous to those 
presented in Table 4-2. These associations however did not remain 
significant in the subset analysis looking at subjects without possible 
symptoms of Crohns disease or GI drugs (Table 4-7). 
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 All subjects 
Number exposed 
Group 
Cases (N=587) Controls (N=1460) 
OR 95% CI 
       
Antibacterials 418 843 1.32 1.05 to 1.65 
Drugs for cardiovascular disease 127 260 1.26 0.95 to 1.66 
Drugs for nervous system disease 275 520 1.34 1.08 to 1.66 
Oral contraceptive pills 94 198 1.48 1.00 to 2.17 
 
 
Table 4-6  Multivariate regression models of different drug groups in all subjects. 
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 All subjects 
Number exposed 
Group 
Cases (N=252) Controls (N=1022) 
OR 95% CI 
       
Antibacterials 163 500 1.53 1.12 to 2.07 
Drugs for cardiovascular disease 41 139 1.49 0.97 to 2.29 
Drugs for nervous system disease 70 274 0.93 0.67 to 1.29 
Oral contraceptive pills 37 121 1.42 0.81 to 2.47 
 
 
Table 4-7 Multivariate regression models of different drug groups in subjects with no symptoms or GI drugs.
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4.3.6. Attributable risk 
Based on the observed OR of 1.32 for any antibiotic exposure and 
the observed 81% of the cases using antibiotics over the  period 
between 2 and 5 years prior to diagnosis the calculated PAF was 
17%. The equivalent figure for current smoking was 10%. 
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4.4. Discussion 
 
This study is the first to examine in detail antibiotic use as a risk 
factor for Crohn's disease and the first to examine it in adults.  It 
provides evidence of an association between antibiotic use and the 
subsequent diagnosis of Crohn's disease. A variety of factors 
suggest that this association is real but a lack of specificity suggests 
that its causality is uncertain. The study also throws some light upon 
the previously described association between Crohn's disease and 
the use of the oral contraceptive pill since although we have 
replicated this result similar questions are raised as to whether this 
association is causal.  
 
The use of the GPRD to carry out this study confers a number of 
benefits.  Firstly unlike the two previous studies in which antibiotic 
use was ascertained after the diagnosis of Crohn's disease33, 34, this 
study utilizes data on antibiotic use which was collected before the 
diagnosis was made. This establishes clearly that the associations 
found in previous studies are unlikely to have resulted solely from 
bias with respect to recall of antibiotic use.  Recall bias cannot 
explain any of the associations found in this study.  In addition the 
use of a complete cohort of eligible patients from a large, 
representative database, and an appropriate group of controls 
makes selection bias unlikely. 
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So if the association was not the result of bias, could it be due to 
confounding? There are few known risk factors for Crohn's disease, 
with age, sex, smoking and family history being the most important.  
Of these we have data on all but family history and have therefore 
been able to construct a multivariate model correcting for the effects 
of age, sex and smoking. We have been unable to adjust for 
possible confounding by family history although for this to be a 
confounder it would need to be associated with antibiotic use, which 
seems unlikely. The data available on smoking are incomplete and it 
is possible that some confounding remains. However as the effect of 
adjusting for smoking classified as smoker/non-smoker was so small 
it seems highly unlikely that the associations demonstrated are 
explained by residual confounding by smoking.  As well as being 
incomplete the smoking data within GPRD is likely to suffer from 
some degree of misclassification.  There is reason to believe that 
some ex-smokers are coded as non-smokers in GPRD, but that 
current smokers may be more accurately coded73. For this reason 
we conducted an analysis limited to current smokers as a further 
check for confounding by smoking status. The results of this 
analysis showed that the association we report remained present in 
this subgroup with the point estimate for the Odds ratio being slightly 
greater. The small numbers of subjects involved however led to a 
lack of precision in this estimate.  
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We considered two other potential artifacts: reverse causation and a 
possible tendency to receive prescriptions. A challenge for any 
study examining the aetiology of a chronic disease is to define date 
of onset accurately, and hence to establish whether exposures 
preceded the onset of symptoms. This is necessary to exclude 
reverse causation, the situation when an exposure is in fact a 
response to symptoms of the still undiagnosed disease.  Although 
the date of diagnosis of inflammatory bowel diseases has been 
validated within GPRD and found to be accurate to within a few 
weeks 77, it is likely that for  a proportion of patients the time 
between  onset of  symptoms and  diagnosis can be long, as shown 
by the analysis in Figure 4-1. Also the age distribution of our cases 
is rather older than would be expected of inident cases of Crohns 
disease. Although this might be explained by the catchment 
population for GPRD having an age distribution different to the UK 
population, the possibility must be considered that a proportion of 
these cases might not truly be incident. Thus it remains possible that 
the association seen may at least in part be due to antibiotics 
prescribed as treatment for the symptoms of undiagnosed Crohn's 
disease or of Crohns disease which has been previously diagnosed 
but not recorded in the GPRD record.  We corrected for this by firstly 
excluding from our multivariate analyses the two year period before 
diagnosis in which symptoms were common; and secondly by 
repeating all analyses in the subgroup of cases with no 
gastrointestinal symptoms or prescription of gastrointestinal drugs 
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within the period from 2-5 years prior to diagnosis. The fact that the 
association between antibiotics and Crohns disease remains, and is 
of the same magnitude in the subgroup analysis, gives some 
evidence against the association being a result of reverse causation.  
 
To try to correct for the tendency of subjects to receive prescriptions 
we explored whether the association between diagnosis of Crohns 
disease and prescription of antibiotics was specific in three ways. 
Firstly we examined whether the association was limited to specific 
groups of antibiotics.  Although the power available for this analysis 
was limited, we were unable to demonstrate a clear specificity with 
any antibiotic group since although only tetracyclines were found to 
have a significant odds ratio as a subgroup, the confidence interval 
for this odds ratio overlapped those of all other groups.  Secondly 
we examined whether the association was specific to antibiotics as 
opposed to other drug groups.  We found an association similar to 
that for antibiotics with the oral contraceptive pill (this association is 
of similar magnitude to that previously described 80, 81), but also 
found similar associations with cardiovascular and neurological drug 
prescribing.  In each of these cases the association was close to the 
same magnitude but statistically non-significant (in contrast to the 
significant association with antibiotic use). This to some extent 
reflects the frequency of antibiotic use and hence the greater power 
to find associations for this drug group. Finally we included in the 
multivariate model as a factor the number of prescriptions for drugs 
 86
other than antibiotics, and from this there was evidence of some 
degree of confounding:  the association between antibiotic use and 
Crohns decreased from 1.56 to 1.32 when prescriptions for other 
drugs were included in the model. This adjustment however did not 
remove all of the association between antibiotic use and the 
subsequent diagnosis of Crohn's disease. 
 
Both the lack of specificity and the lack of a dose response 
relationship provide some evidence that the association between 
Crohns disease and prior antibiotic use may not be causal. This 
begs the question of what alternative explanations there might be. 
Clearly it is possible that despite our best efforts to exclude reverse 
causality our findings might be explained if Crohn's disease does 
indeed have a longer than generally recognised prodrome, which 
presents non-specifically to clinicians and hence causes a wide 
variety of prescriptions.  Equally it may be that only a proportion of 
cases of Crohn's disease are diagnosed, and that the probability of 
being diagnosed is related to the degree of contact the sufferer has 
with medical services (and hence the number of prescriptions which 
they receive). Finally it is possible that some prescribed drug does 
indeed have a causal relationship with Crohn's disease, and that 
since the prescription of one drug is associated with the prescription 
of others the association we have seen with each drug group is in 
effect a proxy for the association with this causally related drug.  
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Although caution needs to be exercised before accepting the 
hypothesis that there is a causal association between antibiotic use 
and Crohns disease it is equally important to guard against the 
premature rejection of the hypothesis. Despite its advantages the 
dataset we have used for this study has allowed us only to examine 
the effect of recent use of antibiotics. There were very few subjects 
for whom much more than 5 years of data prior to diagnosis were 
available, and almost none with complete data from birth to 
diagnosis. We were therefore unable to examine the possibility that 
a greater and perhaps more specific effect would be seen from 
antibiotic use extending over a longer or earlier period or at a 
particular period of life. One potentially important period would be 
early childhood to which the previous studies of this association 
relate33, 34. 
 
As a by-product of this study we have been able to examine the 
relationship between Crohns disease and prior use of oral 
contraceptives. This is an exposure which has been claimed to exert 
a causal influence on Crohns Disease80, 83, 84. The evidence to 
support this from several previous studies is far from entirely 
supportive of this contention however. Firstly those studies 
previously carried out have had quite varied results reporting odds 
ratios from 0.7 to 2.514. A selective meta-analysis gave a pooled OR 
corrected for confounding by smoking of 1.44 (1.12-1.86) 14. There 
has also been evidence to suggest that there is no dose response in 
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this relationship14, 80, that it is not reversible85, and that unlike the 
relationship with smoking it is not specific to Crohn's disease but is 
found with ulcerative colitis also80, 83. The published studies have in 
general like previous antibiotic studies been based upon patient 
recall of exposure and hence liable to recall bias, and none have 
looked as we have at exposure to other drugs. Our finding of an OR 
of 1.48 in our corrected model for oral contraceptive use is 
consistent with previous findings, but the lack of specificity that we 
have shown is yet one further factor which casts doubt on its 
causality in our study and in the previous studies. 
 
In conclusion we have demonstrated a significant association 
between antibiotic use and diagnosis of Crohn's disease 2 to 5 
years later in prospectively collected data. That we have not 
demonstrated a specific association does not disprove the 
hypothesis that antibiotics can contribute to the causation of 
Crohns. In view of the potential importance of the association with 
antibiotics  (that if causal it might account for 17% of Crohns 
disease), and the possibility that the time period available for study 
may not be the most appropriate further study of this question is 
clearly required. 
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Chapter 5. The dataset used for subsequent chapters 
5.1. Introduction 
This chapter will briefly describe the selection of the cohorts of 
subjects used in the subsequently described studies (Mortality in 
Inflammatory Bowel Disease and The risk of fracture in patients 
with IBD). It will then go on to detail those aspects of the data 
abstraction and analysis common to both studies as well as giving 
descriptive statistics of the cohorts. For the sake of brevity full code 
lists are in general not included within this or subsequent chapters 
but in Appendix IV. Since the purpose of this chapter is merely to set 
out those elements of the two subsequent studies that are common 
the results presented are not discussed here. 
 
5.2. Selection of subjects 
5.2.1. Criteria for selection of cases 
The object in selecting this cohort was to permit studies of the 
impact of IBD generalisable to contemporary clinical practice in the 
UK. For this reason the only criterion applied for the selection of IBD 
cases was that they should have a coded diagnosis of Inflammatory 
bowel disease at least once in up to standard data. This criterion 
has been previously validated as defining IBD cases with a validity 
of 94% for CD 94% for UC and 80% for indeterminate IBD as judged 
against a gold standard of the diagnosis of the condition being made 
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based upon barium radiology, endoscopic examination, the opinion 
of a gastroenterologist or a combination of these 77. Our list of codes 
to define cases was similar to that used in this validation study 
(Table 5-1, Table 5-2, Table 5-3). Hereafter the date of the first 
coded episode of IBD for each case is referred to as their index 
date. 
 
 
Code  Description 
 0092LR  Regional Iletis 
 5630C  Regional Colitis 
 5630CR  Crohn's Disease 
 5630ER  Enteritis Regional 
J08z900  Orofacial Crohn's Disease 
J40..00  Regional Enteritis - Crohn's Disease 
J40..11  Crohn's Disease 
J400.00  Regional Enteritis Of The Small Bowel 
J400000  Regional Enteritis Of The Duodenum 
J400100  Regional Enteritis Of The Jejunum 
J400200  Crohn's Disease Of The Terminal Ileum 
J400300  Crohn's Disease Of The Ileum Unspecified 
J400400  Crohn's Disease Of The Ileum Nos 
J400z00  Crohn's Disease Of The Small Bowel Nos 
J401.00  Regional Enteritis Of The Large Bowel 
J401000  Regional Enteritis Of The Colon 
J401100  Regional Enteritis Of The Rectum 
J401z00  Crohn's Disease Of The Large Bowel Nos 
J401z11  Crohn's Colitis 
J402.00  Regional Ileocolitis 
J40z.00  Regional Enteritis Nos 
Jyu4000  [X]Other Crohn's Disease 
N031100  Arthropathy In Crohn's Disease 
N045300  Juvenile Arthritis In Crohn's Disease 
 
Table 5-1 Codes used to define Crohns disease 
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Code  Description 
 5631  Ulcerative Colitis 
14C4.11  H/O: Ulcerative Colitis 
J41..12  Ulcerative Colitis And/Or Proctitis 
J410.00  Ulcerative Proctocolitis 
J410100  Ulcerative Colitis 
J410200  Ulcerative Rectosigmoiditis 
J410300  Ulcerative Proctitis 
J410z00  Ulcerative Proctocolitis Nos 
Jyu4100  [X]Other Ulcerative Colitis 
N031000  Arthropathy In Ulcerative Colitis 
N045400  Juvenile Arthritis In Ulcerative Colitis 
 
 
Table 5-2  Codes used to define Ulcerative colitis 
 
 
Code  Description 
   92N  Inflammatory Bowel Disease 
J4...12  Inflammatory Bowel Disease 
J41z.00  Idiopathic Proctocolitis Nos 
 
 
Table 5-3 Codes used to define indeterminate IBD 
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5.2.2. Criteria for selection of controls 
Controls were matched and chosen by the following criteria 
x Same sex as their matched case. 
x Age within 5 years of the case. 
x Registered at the same General practice as the case. 
x Alive and contributing data to GPRD on the index date of the 
case (the date of the first coded episode of IBD in up to 
standard data). (This date hence is also the index date for the 
control hereafter.) 
x No record of IBD at any time in their GPRD record. 
 
Among those meeting these criteria 5 were chosen randomly (or all 
were taken if 5 or less were available). 
5.3. Importation of data and basic error checking of selection. 
All data manipulation and analysis within for these studies were 
conducted in Stata 7 SE (Stata Corporation, 4905 Lakeway Drive, 
College Station, Texas 77845, USA ). On importation to this 
program it was found that some dates did not fit the correct data 
format having only year indicated, these were dealt with by ascribing 
a date of 1st July of the indicated year. Cases and controls were 
checked to ensure that no subjects belonged to both sets. Further 
error checking and exclusions were carried out when extracting 
specific data. Data entered more than once identically were counted 
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only once when extracting data, and impossible data (such as 
events or prescriptions prior to birth or after death) were ignored. 
 
5.4. Basic data extracted  
5.4.1. Defining subtypes of IBD 
IBD type was classified based on the codes listed above. Where a 
subject had codes related to only one form of IBD they were 
considered to have this form of disease. Subjects were classified as 
having indeterminate IBD if they had codes for both UC and CD, as 
having UC if codes both for non-specific IBD and UC were present 
and as having CD if codes for both this and for non-specific IBD 
were found.  
 
5.4.2. Diagnosis date of IBD 
The diagnosis date of IBD was defined as being the earliest event 
date for an episode coded with any of the IBD codes listed above. 
Each control was assigned a pseudo-diagnosis date identical to the 
diagnosis date of their case. 
5.4.3. Incident and prevalent cases 
Subjects having a diagnosis of IBD coded as occurring first at least 
two years after their collection of prospective data in GPRD began 
were considered to be incident cases. All other subjects were 
considered prevalent.  
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5.4.4. Age and sex 
Since sex and date of birth are both recorded for all GPRD subjects 
directly, it was necessary to determine only the point in time at 
which age should be measured in order to define these data. For the 
purposes of the studies presented below age when used as a 
covariate in analyses is defined as the age at the index date for 
each subject. 
 
5.4.5. Smoking 
Subjects smoking status was classified based upon the coding 
during up to standard data in both the medical and prevention tables 
of GPRD as unknown, never a smoker, ex smoker or current 
smoker.  Where smoking was referred to by Oxmis or Read codes 
this coding of behaviour was based upon the codes listed in Table 
IV-6, and where it was referred to as a number of cigarettes smoked 
in the prevention table subjects smoking 1 or more were considered 
smokers and those smoking none non-smokers. Subjects who 
appeared in more than one of these categories at differing times 
were coded in the category suggesting greatest smoking 
experience.  
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5.4.6.  BMI 
All data coding height and weight during up to standard data 
recording were identified from the prevention table. Since BMI is a 
measure of questionable validity in children data recorded when 
subjects were aged under 18 was ignored. Inspection of the data 
showed large numbers of outliers that recorded impossible or highly 
unlikely figures (weights or heights of zero for example as well as 
heights of as much as 4 metres). Records of height over 2.5 metres 
or under 1 metre were therefore ignored as being probable errors as 
well as records coding a weight under 30kg.  In each of these cases 
the excluded data were mostly at least an order of magnitude 
different to these limits which since data are entered as 1000 times 
the weight in kilos or the height in metres might suggest that an 
incorrect number of zeros had been entered. BMI was calculated as 
the median of an individuals weight records in kg divided by the 
square of the median of their height records in metres. 
 
5.4.7. Systolic Blood Pressure 
Systolic blood pressure is recorded in the prevention table of GPRD 
and was extracted directly from this source. As for height and weight 
some very unlikely values were found in the data. Values above 
300mm of Hg or below 50 were therefore ignored as being likely to 
be either errors or indicative of current acute ill health (as opposed 
to being a long term indicator of risk for future ill health). The final 
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blood pressure value used in analyses is the median of all recorded 
values for a subject during the up to standard data recording period. 
 
 
5.5. Results of basic data extraction 
5.5.1. Numbers in the cohorts 
In total there were 16,550 people with IBD and 82,917 appropriately 
matched controls. Within the IBD cohort 5,960 (36%) people had 
Crohns disease, 8,301 (50%) had ulcerative colitis and 2,289 
(14%)had indeterminate IBD. Table 5-4 
 
5.5.2. Age and sex 
 The average age at entry to the study was 46 years for both IBD 
cases and controls, and 46% of each cohort were male. Table 5-4 
 
5.5.3. Incident and prevalent status 
Among the IBD cases 5631 (34%) were incident, and 10919 (66%) 
were prevalent. The age at diagnosis was lower among the 
prevalent cases with a mean of 40 years compared to 47 years in 
incident cases. Table 5-4
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IBDtype   All IBD   UC   Crohns   indeterminate 
    case control   Case control   case control   case control
Number N 16551 82917  8301 41589  5961 29843  2289 11485 
Female % 53.6 53.7  48.9 48.9  58.7 58.8  57.2 57.3 
Male % 46.4 46.3  51.1 51.1  41.3 41.2  42.8 42.7 
Age at entry                 
  under 20 % 5.4 5.4  3.2 3.2  8.2 8.2  5.9 5.9 
  20-39 % 38.7 38.6  34.4 34.3  44.5 44.4  39.3 39.0 
  40-59 % 32.2 32.1  35.4 35.3  28.2 28.2  30.8 30.5 
  60-79 % 19.8 20.0  22.8 23.0  15.7 15.9  19.8 20.0 
  80 or over % 3.9 4.0  4.1 4.3  3.3 3.4  4.3 4.6 
Mean    46.2 46.3  48.6 48.7  42.8 42.9  46.1 46.3 
SE   0.1 0.1  0.2 0.1  0.2 0.1  0.4 0.2 
% incident  34   33   31   46  
mean age at diagnosis 47.3   50.0   43.0   47.5  
% prevalent  66   67   69   54  
mean age at diagnosis 39.7   41.8   36.6   41.1  
 
Table 5-4 Demographic details of cases and controls subdivided by disease type
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5.5.4. Smoking 
Smoking was more common amongst Crohns cases than among 
the control cohort (28% smokers versus 21% of their matched 
controls) and less common among UC cases (12% versus 20%), 
indeterminate cases had intermediate levels of smoking (22% 
versus 21%). There was less missing data for cases. These results 
are summarised in Table 5-5. 
 
5.5.5. BMI 
The IBD cohort had a slightly lower BMI than did controls. Overall 
the mean of their BMIs was 24.72 as opposed to 25.48 for the 
control cohort, and they were more likely to have a BMI under 25 
(36% versus 29%) Table 5-6. These differences were most marked 
among the Crohns cases for whom the comparison between mean 
BMIs was 24.02 for cases versus 25.25 for controls. Likewise 
between the Crohns cases and their controls their was a greater 
disparity between the proportions of low or high BMI with 40% of the 
Crohns cases having a BMI below 25 compared to 29% of their 
controls. Again there was less missing data for cases. 
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  Case 
 Control 
  Number
%  Number % 
   
  
  
 never smoker 477 3 
 
2189 3 
 non smoker 6983 42
 
30680 37 
ex smoker 887 5 
 
3289 4 
 current smoker 3209 19
 
17110 21 
ALL IBD 
 Unknown 4995 30
 
29649 36 
       
 never smoker 259 3  1094 3 
 non smoker 3945 48  15511 37 
 ex smoker 541 7  1770 4 
 current smoker 1027 12  8442 20 
UC 
 Unknown 2529 31  14772 36 
       
 never smoker 144 2  773 3 
 non smoker 2107 35  10888 37 
 ex smoker 226 4  1051 4 
 current smoker 1682 28  6265 21 
CD 
 Unknown 1802 30  10866 36 
       
 never smoker 74 3  322 3 
 non smoker 931 41  4281 37 
 ex smoker 120 5  468 4 
 current smoker 500 22  2403 21 
Indeterminate 
 Unknown 664 29  4011 35 
 
Table 5-5 Smoking behaviour by IBD type and case status 
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 BMI Case Control 
  Number
% Number % 
   
 
  
  <19 544 3 1570 2 
  19-24 5454 33 21948 26 
  25-29 2990 18 15371 19 
  30-34 848 5 4657 6 
  >35 263 2 1657 2 
  Unknown 6452 39 37714 45 
ALL IBD 
Mean (SE) 24.72 0.04 25.48 0.02 
      
  <19 167 2 698 2 
  19-24 2626 32 10722 26 
  25-29 1703 21 8263 20 
  30-34 490 6 2395 6 
  >35 147 2 838 2 
  Unknown 3168 38 18673 45 
UC 
Mean (SE) 25.22 0.06 25.63 0.03 
      
  <19 301 5 647 2 
  19-24 2067 35 8124 27 
  25-29 863 14 4952 17 
  30-34 236 4 1595 5 
  >35 87 1 580 2 
  Unknown 2407 40 13945 47 
CD 
Mean (SE) 24.02 0.03 25.25 0.04 
      
  <19 76 3 225 2 
  19-24 761 33 3102 27 
  25-29 424 19 2156 19 
  30-34 122 5 667 6 
  >35 29 1 239 2 
  Unknown 877 38 5096 44 
Indeterminate 
Mean (SE) 24.69 0.12 25.49 0.06 
 
Table 5-6 Body mass index by case status and IBD type. 
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5.5.6. Blood Pressure 
The recorded blood pressures of the IBD cohort were lower than 
those of controls with a mean systolic BP of 130 for cases and 133 
for controls.  The difference in mean values between cases and 
controls was similar for each IBD type, but the difference in the 
proportion of cases and controls with a systolic BP below 120 was 
greater for Crohns disease. 
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  Case 
 Control 
  Number
%  Number % 
   
  
  
Under 100 239 1  710 1 
100-119 3250 20  12914 16 
120-139 4885 30  22335 27 
140-159 2979 18  14702 18 
over 160 1293 8  7402 9 
Unknown 3905 24  24854 30 
ALL IBD 
Mean (SE) 130 (0.18)  133 (0.08) 
       
under 100 82 1  328 1 
100-119 1346 16  5665 14 
120-139 2552 31  11158 27 
140-159 1728 21  8159 20 
over 160 718 9  4155 10 
Unknown 1875 23  12124 29 
UC 
Mean (SE) 132 (0.24)  134 (0.12) 
       
under 100 127 2  283 1 
100-119 1402 24  5346 18 
120-139 1649 28  7994 27 
140-159 854 14  4533 15 
over 160 392 7  2200 7 
Unknown 1537 26  9487 32 
CD 
Mean (SE) 127 (0.30)  130 (0.14) 
       
under 100 30 1  99 1 
100-119 502 22  1903 17 
120-139 684 30  3183 28 
140-159 397 17  2010 18 
over 160 183 8  1047 9 
Unknown 493 22  3243 28 
Indeterminate 
Mean (SE) 129 (0.46)  132 (0.22) 
 
Table 5-7 Systolic blood pressure by case status and IBD type.
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Chapter 6. Mortality in Inflammatory Bowel Disease 
6.1. Introduction 
This chapter presents a study of the mortality associated with IBD 
that uses the GPRD cohorts described in Chapter 5. 
 
6.2. Methods 
6.2.1. Identifying deaths. 
For each subject we used a combination of Oxmis and Read coding  
(Table IV-7) and the subjects registration status within GPRD to 
assess whether they had died. Where a subject was multiply 
recorded as having died we used the earliest recorded date to 
define the date of death.  
6.2.2. Co morbidity measures 
To allow adjustment for the effect of co-morbidities we used two 
approaches. Firstly we used the Charlson index 86 (Table 6-1) as a 
composite measure of co-morbidity for use as a confounder in 
multivariate analyses. For this subjects were scored based upon co 
morbidities coded prior to entry to the study before calculation of the 
score. Secondly we formed healthy cohorts both of IBD cases and 
controls by excluding subjects with ischaemic heart disease, heart 
failure, hypertension, COPD, asthma, renal disease, any malignancy 
and diabetes. The presence of these conditions was assessed using 
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a combination of Oxmis and Read codes, with analysis again limited 
to disease recorded before entry to the study. (The codes used for 
this analysis were identical to those used for the relevant co 
morbidities in the Charlson index with the exception of hypertension 
codes for which are given in Table IV-28). We then carried out 
analyses in these restricted cohorts. As well as stratifying for co-
morbidity these cohorts approximately illustrate the risks of subjects 
not loaded for life insurance for reasons other than IBD. 
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Score  Condition 
 Myocardial infarct 
 Congestive heart failure 
 Peripheral vascular disease 
 Cerebrovascular disease 
 Dementia 
 Chronic pulmonary disease 
 Connective tissue disease 
 Ulcer disease 
 Mild liver disease 
1 
 Diabetes 
   
 Hemiplegia 
 Moderate or severe renal disease 
 Diabetes with end organ damage 
 Any tumour 
 Leukaemia 
2 
 Lymphoma 
   
3  Moderate or severe liver disease 
   
 Metastatic solid tumour 
6 
 AIDS 
 
Table 6-1 The Charlson index 
 
A subject gains the score of each of the conditions listed from which 
he/she suffers. The overall score is the sum of all of these individual 
comorbidity scores. 
 
(Codes used for this scoring are given in Table IV-8 to Table IV-26.)
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6.2.3. Univariate analysis 
Univariate analysis of mortality using the matched cohort design 
was conducted by the production of crude mortality rates (for which 
95% confidence intervals were calculated based upon the Poisson 
distribution), survival plots and log rank tests. In each case the origin 
of the time axis and the entry of the subject to the study were both 
set as the date of the first prospectively recorded IBD code (the 
matched cases relevant date was used for controls).  Additionally 
life tables were created based upon the crude mortality rates 
calculated to allow the comparison of life expectancy for cases and 
controls. Finally as a check upon the likely validity of the GPRD 
database for studies of this sort we calculated standardised mortality 
ratios (standardised to annual age and sex specific national 
mortality figures for England and Wales), for both cases and 
controls. Because national statistics were available only until 1999 it 
was necessary to truncate the data at that point.
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6.2.4. Multivariate analysis 
Multivariate analyses were conducted using a Cox regression 
model, and the validity of the assumption of proportional hazards 
was assessed using Log Log plots. As age, sex, and smoking are all 
known to be associated with both the risk of IBD and the risk of 
death they were all included within our models on an a priori basis. 
Other potential confounding factors added to this base model were 
retained only if they resulted in a 10% or greater change in the 
hazard ratio. For BMI, and blood pressure as for smoking the 
confounding variable was included in the analysis as a categorical 
variable with a category representing missing data. The multivariate 
analyses were repeated stratifying both for disease type and age 
group at entry. Tests for interaction by these groups were carried 
out. In addition restriction analyses were carried out to examine the 
risks among incident cases of IBD, prevalent cases and those with a 
recorded date of first diagnosis at least five years prior to entry to 
the study (i.e. prevalent cases with at least a five year history). A 
further restriction analysis was carried out after exclusion of all 
subjects with the chronic diseases specified above.  
To check the robustness of our results we attempted to increase 
diagnostic specificity by limiting our analyses to cases with at least 
two episodes coded as IBD.  To examine the reliability of death 
recording within GPRD and the possibility of bias within it (due to the 
possibility that controls may be more likely to move away without 
their GP knowing, and therefore more likely to die without it being 
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recorded) we repeated the analysis excluding all subjects with no 
recorded medical data dated within the last year of their data. Since 
a diagnosis is more likely to be recorded at a time when it is causing 
ill health (even if it is a longstanding condition) we examined the 
effect of censoring data for one or two years from the date of entry 
to the study. Lastly to investigate whether misclassification of ex-
smokers as non-smokers may have affected our results we carried 
out an analysis limited to current smokers. 
 
All analyses were conducted using Stata version 7. 
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6.3. Results 
6.3.1. Univariate analysis of mortality 
The IBD cohort contributed 61,215 years of follow up and 1,047 
deaths and controls 306,183 years of follow up and 3,758 deaths. 
These corresponded to crude mortality rates of 17.1 per thousand 
person years for cases and 12.3 per thousand patient years for 
controls (Table 6-2). 
 
 
 Deaths Follow up
Mortality 
Rate 
95% 
CI 
Rate 
difference 
       
Case 1047 61.2 17.1 16 18  
       
Control 3758 306.2 12.3 12 13 4.8 
 
Table 6-2 Crude mortality rates for all cases and all controls. 
(Follow up is quoted as thousands of person years: Mortality rate 
and Rate difference are quoted per 103 person years) 
 
 A breakdown of deaths, follow up available and crude rates by 
disease and age at entry to the study are given in Table 6-4. The 
absolute mortality rate difference between cases and controls was 
higher in the older age groups (rate differences in the over 80s of 
39.2 deaths per 1000 person years for UC and 55.9 deaths per 
thousand person years for Crohns disease) than among the young 
(rate differences in the under 20s of 0.5 deaths per 1000 person 
years for UC and 1.0 death per thousand person years for Crohns 
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disease). Overall the mortality rate difference was higher for Crohns 
disease (6.2 deaths per 1000 person years) than for UC (3.7 deaths 
per 1000 person years) or indeterminate IBD (5.3 deaths per 1000 
person years). These small excesses of mortality are shown 
graphically by Kaplan Meier plots in Figure 6-1, Figure 6-2, Figure 
6-3 and Figure 6-4. Expressing these results as hazard ratios via a 
univariate Cox regression model showed hazard ratios of 1.39 for all 
IBD, 1.27 for UC, 1.62 for CD, and 1.40 for indeterminate IBD (Table 
6-3). 
 
 
 
 HR 95 % confidence  interval 
All IBD 1.39 1.30 to 1.49 
UC 1.27 1.16 to 1.40 
CD 1.62 1.44 to 1.83 
Indeterminate IBD 1.40 1.17 to 1.66 
Table 6-3 Univariate Cox regression models
  111
  Case Control  
IBD type 
Age 
group 
Deaths 
Follow up 
(/10
3
 years)
Mortality
Rate 
95% CI Deaths 
Follow up 
(/10
3
 years)
Mortality 
Rate 
95% CI 
Rate difference 
/10
3
 person yrs 
  under 20  0 0.9 0.0 . .  0 4.3 0.0 . . 0.0 
  20-39  15 10.6 1.4 0.9 2.4  46 51.3 0.9 0.7 1.2 0.5 
  40-59  95 12.0 7.9 6.5 9.7  297 59.1 5.0 4.5 5.6 2.9 
  60-79  290 6.8 42.6 38.0 47.8  1167 35.3 33.0 31.2 35.0 9.6 
 80 or over  136 0.8 161.8 136.8 191.4  586 4.8 122.6 113.1 132.9 39.2 
UC 
Total  536 31.1 17.3 15.9 18.8  2096 154.8 13.5 13.0 14.1 3.7 
  under 20  2 1.6 1.2 0.3 4.9  2 8.0 0.3 0.1 1.0 1.0 
  20-39  22 9.4 2.3 1.5 3.6  27 46.2 0.6 0.4 0.9 1.8 
  40-59  58 6.6 8.7 6.8 11.3  163 33.3 4.9 4.2 5.7 3.8 
  60-79  187 3.4 55.1 47.7 63.6  591 18.6 31.8 29.3 34.5 23.3 
 80 or over  82 0.5 160.0 128.8 198.6  312 3.0 104.0 93.1 116.3 55.9 
Crohns 
Total  351 21.6 16.3 14.6 18.0  1095 109.2 10.0 9.5 10.6 6.2 
  under 20  0 0.5 0.0 . .  1 2.5 0.4 0.1 2.8 -0.4 
  20-39  4 3.4 1.2 0.5 3.2  16 15.9 1.0 0.6 1.6 0.2 
  40-59  28 2.8 10.2 7.0 14.7  59 13.8 4.3 3.3 5.5 5.9 
  60-79  87 1.7 51.5 41.7 63.6  316 8.6 36.7 32.8 40.9 14.9 
 80 or over  41 0.2 198.9 146.5 270.1  175 1.4 129.6 111.7 150.3 69.3 
Indeterminate 
Total  160 8.5 18.8 16.1 21.9  567 42.2 13.5 12.4 14.6 5.3 
 
Table 6-4 Deaths, follow up time, crude mortality rates and rate differences between cases and controls by IBD type and age band. 
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Figure 6-1 Kaplan Meier plot of all cause mortality for all IBD 
patients versus controls 
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Figure 6-2 Kaplan Meier plot of all cause mortality for UC patients 
versus controls
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Figure 6-3 Kaplan Meier plot of all cause mortality for Crohns 
disease versus controls 
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Figure 6-4 Kaplan Meier plot of all cause mortality for indeterminate 
IBD versus controls.
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6.3.2. Life table analysis 
 
The life tables (Table 6-5, Table 6-6, Table 6-7, Table 6-8, Table 
6-9, Table 6-10) demonstrate that the IBD cases overall have a 
roughly 3.5 year lower life expectancy than their controls on 
average. With advancing age this difference diminishes so that by 
the age of 60 the life expectancy of an IBD case is only about 1.5 
years lower than that of a control. 
 
These differences are more marked for cases with Crohns disease  
(who have on average an 5 year lower life expectancy than their 
controls) but less for those with UC (who have on average an 2.3 
year lower life expectancy than their controls). 
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Age group Deaths observed Years observed Mortality Rate Qx Px lx dx Lx Tx ex 
           
0 0 99 0.0000 0.000 1.000 1000 0.00 5000 75024 75.02 
5 0 574 0.0000 0.000 1.000 1000 0.00 5000 70024 70.02 
10 0 2304 0.0000 0.000 1.000 1000 0.00 5000 65024 65.02 
15 2 5174 0.0004 0.002 0.998 1000 1.93 4995 60024 60.02 
20 3 12620 0.0002 0.001 0.999 998 1.19 4987 55029 55.14 
25 12 22978 0.0005 0.003 0.997 997 2.60 4978 50041 50.20 
30 19 29667 0.0006 0.003 0.997 994 3.18 4963 45063 45.32 
35 26 30572 0.0009 0.004 0.996 991 4.21 4945 40100 40.46 
40 37 30871 0.0012 0.006 0.994 987 5.90 4920 35155 35.62 
45 82 32488 0.0025 0.013 0.987 981 12.30 4874 30235 30.82 
50 99 27977 0.0035 0.018 0.982 969 16.99 4801 25361 26.18 
55 159 22253 0.0071 0.035 0.965 952 33.40 4675 20560 21.60 
60 211 21412 0.0099 0.048 0.952 918 44.16 4481 15885 17.30 
65 395 20285 0.0195 0.093 0.907 874 81.16 4168 11404 13.05 
70 560 18227 0.0307 0.143 0.857 793 113.13 3682 7236 9.12 
75 696 14059 0.0495 0.220 0.780 680 149.75 3025 3554 5.23 
80 1457 14623 0.0996 0.399 0.601 530 211.43 529 529 1.00 
 
Table 6-5 Life table for controls of all IBD 
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Age group Deaths observed Years observed Mortality Rate Qx Px lx dx Lx Tx ex 
           
0 0 20 0.0000 0.000 1.000 1000 0.00 5000 71531 71.53 
5 0 109 0.0000 0.000 1.000 1000 0.00 5000 66531 66.53 
10 0 450 0.0000 0.000 1.000 1000 0.00 5000 61531 61.53 
15 1 1043 0.0010 0.005 0.995 1000 4.78 4988 56531 56.53 
20 3 2626 0.0011 0.006 0.994 995 5.67 4962 51543 51.79 
25 6 4751 0.0013 0.006 0.994 990 6.23 4932 46581 47.07 
30 10 6183 0.0016 0.008 0.992 983 7.92 4897 41649 42.36 
35 13 6213 0.0021 0.010 0.990 975 10.15 4852 36753 37.68 
40 18 6332 0.0028 0.014 0.986 965 13.62 4792 31901 33.05 
45 29 6621 0.0044 0.022 0.978 952 20.61 4707 27109 28.49 
50 46 5607 0.0082 0.040 0.960 931 37.42 4561 22402 24.06 
55 42 4441 0.0095 0.046 0.954 894 41.28 4365 17841 19.97 
60 70 4261 0.0164 0.079 0.921 852 67.25 4093 13476 15.81 
65 124 3977 0.0312 0.145 0.855 785 113.53 3641 9383 11.95 
70 167 3461 0.0482 0.215 0.785 672 144.56 2996 5741 8.55 
75 169 2569 0.0658 0.282 0.718 527 148.84 2263 2745 5.21 
80 349 2549 0.1369 0.510 0.490 378 192.84 482 482 1.27 
 
Table 6-6 Life table for all IBD cases
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Age group Deaths observed Years observed Mortality Rate Qx Px lx dx Lx Tx ex 
           
0 0 31 0.0000 0.000 1.000 1000 0.00 5000 75212 75.21 
5 0 159 0.0000 0.000 1.000 1000 0.00 5000 70212 70.21 
10 0 1034 0.0000 0.000 1.000 1000 0.00 5000 65212 65.21 
15 1 2978 0.0003 0.002 0.998 1000 1.68 4996 60212 60.21 
20 1 6836 0.0001 0.001 0.999 998 0.73 4990 55216 55.31 
25 5 10501 0.0005 0.002 0.998 998 2.37 4982 50227 50.35 
30 7 12839 0.0005 0.003 0.997 995 2.71 4969 45245 45.46 
35 8 11678 0.0007 0.003 0.997 993 3.39 4954 40275 40.58 
40 9 10466 0.0009 0.004 0.996 989 4.24 4935 35321 35.71 
45 28 10217 0.0027 0.014 0.986 985 13.40 4891 30386 30.85 
50 36 8624 0.0042 0.021 0.979 971 20.07 4807 25495 26.24 
55 49 6902 0.0071 0.035 0.965 951 33.18 4674 20688 21.74 
60 58 6586 0.0088 0.043 0.957 918 39.56 4492 16014 17.44 
65 109 6050 0.0180 0.086 0.914 879 75.74 4204 11522 13.11 
70 157 5429 0.0289 0.135 0.865 803 108.27 3744 7318 9.11 
75 210 4156 0.0505 0.224 0.776 695 155.80 3084 3574 5.14 
80 417 4687 0.0890 0.364 0.636 539 196.09 490 490 0.91 
 
 
Table 6-7 Life table for Crohns disease controls 
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Age group Deaths observed Years observed Mortality Rate Qx Px lx dx Lx Tx ex 
           
0 0 6 0.0000 0.000 1.000 1000 0.00 5000 70207 70.21 
5 0 31 0.0000 0.000 1.000 1000 0.00 5000 65207 65.21 
10 0 195 0.0000 0.000 1.000 1000 0.00 5000 60207 60.21 
15 1 588 0.0017 0.008 0.992 1000 8.46 4979 55207 55.21 
20 2 1435 0.0014 0.007 0.993 992 6.89 4940 50228 50.66 
25 4 2177 0.0018 0.009 0.991 985 9.01 4901 45287 45.99 
30 4 2644 0.0015 0.008 0.992 976 7.35 4860 40387 41.39 
35 8 2341 0.0034 0.017 0.983 968 16.41 4800 35527 36.69 
40 5 2081 0.0024 0.012 0.988 952 11.37 4731 30726 32.28 
45 11 2048 0.0054 0.026 0.974 941 24.92 4640 25995 27.64 
50 20 1706 0.0117 0.057 0.943 916 52.16 4448 21355 23.32 
55 12 1373 0.0087 0.043 0.957 863 36.92 4225 16907 19.58 
60 21 1317 0.0159 0.077 0.923 827 63.37 3974 12682 15.34 
65 38 1197 0.0318 0.147 0.853 763 112.27 3535 8708 11.41 
70 67 957 0.0700 0.298 0.702 651 193.97 2770 5173 7.95 
75 46 720 0.0639 0.275 0.725 457 125.82 1970 2404 5.26 
80 112 789 0.1419 0.524 0.476 331 173.38 433 433 1.31 
 
 
Table 6-8 Life table for Crohns disease cases 
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Age group Deaths observed Years observed Mortality Rate Qx Px lx dx Lx Tx ex 
           
0 0 19 0.0000 0.000 1.000 1000 0.00 5000 75081 75.08
5 0 265 0.0000 0.000 1.000 1000 0.00 5000 70081 70.08
10 0 869 0.0000 0.000 1.000 1000 0.00 5000 65081 65.08
15 0 1379 0.0000 0.000 1.000 1000 0.00 5000 60081 60.08
20 1 3819 0.0003 0.001 0.999 1000 1.31 4997 55081 55.08
25 5 9099 0.0005 0.003 0.997 999 2.74 4987 50084 50.15
30 7 12483 0.0006 0.003 0.997 996 2.79 4973 45097 45.28
35 13 14912 0.0009 0.004 0.996 993 4.32 4955 40125 40.40
40 22 16228 0.0014 0.007 0.993 989 6.68 4928 35170 35.57
45 43 17852 0.0024 0.012 0.988 982 11.76 4881 30242 30.79
50 58 15647 0.0037 0.018 0.982 970 17.82 4807 25361 26.13
55 91 12702 0.0072 0.035 0.965 953 33.52 4679 20553 21.58
60 125 12185 0.0103 0.050 0.950 919 45.96 4480 15874 17.27
65 229 11860 0.0193 0.092 0.908 873 80.41 4164 11394 13.05
70 317 10078 0.0315 0.146 0.854 793 115.58 3674 7229 9.12
75 392 7845 0.0500 0.222 0.778 677 150.39 3010 3555 5.25
80 793 7596 0.1044 0.414 0.586 527 218.04 545 545 1.03
 
 
Table 6-9 Life table for UC controls 
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Age group Deaths observed Years observed Mortality Rate Qx Px lx dx Lx Tx ex 
           
0 0 4 0.0000 0.000 1.000 1000 0.00 5000 72748 72.75 
5 0 50 0.0000 0.000 1.000 1000 0.00 5000 67748 67.75 
10 0 174 0.0000 0.000 1.000 1000 0.00 5000 62748 62.75 
15 0 283 0.0000 0.000 1.000 1000 0.00 5000 57748 57.75 
20 0 776 0.0000 0.000 1.000 1000 0.00 5000 52748 52.75 
25 2 1880 0.0011 0.005 0.995 1000 5.31 4987 47748 47.75 
30 4 2618 0.0015 0.008 0.992 995 7.57 4955 42761 42.99 
35 4 3042 0.0013 0.007 0.993 987 6.47 4919 37807 38.30 
40 11 3355 0.0033 0.016 0.984 981 15.95 4863 32887 33.54 
45 14 3652 0.0038 0.019 0.981 965 18.32 4778 28024 29.05 
50 18 3150 0.0057 0.028 0.972 946 26.66 4665 23246 24.56 
55 24 2557 0.0094 0.046 0.954 920 42.17 4493 18581 20.20 
60 39 2439 0.0160 0.077 0.923 878 67.46 4219 14087 16.05 
65 74 2310 0.0320 0.148 0.852 810 120.16 3750 9868 12.18 
70 71 1961 0.0362 0.166 0.834 690 114.52 3163 6118 8.87 
75 100 1468 0.0681 0.291 0.709 575 167.48 2458 2955 5.13 
80 175 1361 0.1286 0.487 0.513 408 198.51 496 496 1.22 
 
 
Table 6-10 Life table for UC cases 
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6.3.3. SMR analysis 
The standardised mortality ratios for all IBD cases and all controls 
(against national figures for England and Wales in appropriate 
years) are set out in Table 6-11. Controls are at significantly 
reduced risk of death when compared to the whole UK population 
(SMR 0.91 (95% CI 0.88-0.94)). 
 
 
 
 
 
  Observed Expected  SMR 95% CI 
        
Cases  981 730  1.34 1.26 1.43 
        
Controls  3612 3977  0.91 0.88 0.94 
 
Table 6-11 SMRs for all IBD cases and controls.
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6.3.4. Multivariate analysis 
In the multivariate Cox regression analysis we included age at entry 
to the study, sex and smoking as confounders on an a priori basis. 
No appreciable further confounding either by Charlson index score, 
BMI or systolic blood pressure was found and hence these were not 
included in the final model.  Overall we found a hazard ratio for 
death among subjects with IBD of 1.54 (1.44-1.65) when corrected 
for age, sex, and smoking habits.  Within this model the hazard ratio 
for death associated with male sex was 1.41 (1.33-1.50) and for 
being a current smoker (compared to a never smoker) was 1.96 
(1.57-2.45).  Subdividing IBD cases by disease type showed that the 
hazard ratio was greater for Crohns disease at 1.73 (1.54-1.96) and 
that it was lower for ulcerative colitis (1.44 (1.31-1.58)). There was 
no statistically significant evidence of interaction between the effects 
of sex or smoking behaviour and IBD but such interaction was 
detected for age group. The hazard ratio for death associated with 
inflammatory bowel diseases was in general larger among younger 
age groups although there were few deaths available for study in the 
youngest age groups.  These results are set out in table Table 6-12. 
Log-log plots for these models  an example of which is shown in 
Figure 6-5 showed no gross violation of the proportional hazards 
assumptions.  
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Age at entry 
(years) 
Deaths among
cases 
Hazard 
Ratio 
95% CI 
     
UC     
  All ages 536 1.44 1.31 1.58 
  under 20 0 1.00 - - 
  20-39 15 1.68 0.94 3.02 
  40-59 95 1.79 1.42 2.27 
  60-79 290 1.37 1.20 1.56 
  80 or over 136 1.37 1.20 1.56 
     
Crohn's     
  All ages 351 1.73 1.54 1.96 
  under 20 2 5.30 0.74 37.87 
  20-39 22 3.82 2.17 6.75 
  40-59 58 1.80 1.33 2.43 
  60-79 187 1.73 1.47 2.04 
  80 or over 82 1.49 1.17 1.90 
     
Indeterminate     
  All ages 160 1.56 1.31 1.86 
  under 20 0 0.00 - - 
  20-39 4 1.31 0.44 3.94 
  40-59 28 2.49 1.59 3.91 
  60-79 87 1.46 1.15 1.86 
  80 or over 41 1.46 1.03 2.05 
     
 
Table 6-12 Hazard ratios for death by age group and type of IBD 
derived from Cox regression models corrected for the effects of sex 
and smoking 
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Figure 6-5 Log log plot for multivariate analysis of mortality for all IBD 
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6.3.5. Restriction analyses 
Table 6-13 shows a series of analyses limited to subsets of the 
available data. The hazard ratios were reduced slightly when the 
analysis was limited to subjects with 2 or more coded episodes of 
IBD (hazard ratio 1.37 for UC, 1.53 for CD, and 1.31 for 
indeterminate disease), and are similarly reduced when subjects 
having no medical codes entered in the final year for which they 
contributed were excluded or when the first year of each subjects 
data after entry was censored (censoring of 2 rather than one year 
made no appreciable additional difference). The limitation of the 
analysis to prevalent cases diagnosed at least 5 years before entry 
to the study slightly reduced the hazard ratio for CD (1.58), but 
increased it for UC (1.49). Further restricting analysis to cases 
diagnosed at least 5 years before entry to the study accentuates this 
change in UC. When only subjects without previously diagnosed 
heart, lung or renal disease malignancy, hypertension or diabetes 
are included a rather larger increase in hazard is seen (hazard ratios 
1.83 for UC and 2.33 for CD). Finally analysis limited to current 
smokers slightly increased the hazard ratio for CD (1.90). 
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 UC CD Indeterminate 
 HR 95% CI HR 95% CI HR 95% CI 
All subjects 1.44 1.31 1.58 1.73 1.54 1.96 1.56 1.31 1.86 
2 or more episodes of IBD coded 1.37 1.22 1.53 1.53 1.33 1.76 1.31 1.01 1.69 
First year of data censored 1.37 1.22 1.53 1.58 1.37 1.82 1.21 0.97 1.52 
2 or more episodes and one year censored 1.36 1.20 1.55 1.50 1.28 1.75 1.16 0.86 1.57 
Incident cases only 1.32 1.10 1.58 2.21 1.77 2.77 1.87 1.42 2.45 
Prevalent cases only 1.49 1.33 1.66 1.58 1.37 1.82 1.38 1.09 1.73 
Cases > 5 years post diagnosis (at entry) 1.69 1.42 2.01 1.58 1.26 1.98 1.27 0.76 2.1 
Subjects without specified morbidity 1 1.83 1.54 2.17 2.33 1.89 2.88 1.97 1.43 2.72 
Excluding subjects with PSC 2 1.41 1.28 1.55 1.74 1.54 1.96 1.54 1.29 1.84 
Excluding subjects with no medical data 
coded in their last year 
1.32 1.20 1.45 1.61 1.43 1.82 1.45 1.22 1.73 
Table 6-13  Cox regression models corrected for age sex and smoking for subgroups of cases and their matched controls. 
(1Specified morbidities are any record of ischaemic heart disease, heart failure, hypertension, COPD, asthma, renal disease, 
any malignancy and diabetes. 2 Codes defining PSC are given in Table IV-27) 
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6.4. Discussion 
 
This study of 1,047 deaths in over 16,000 IBD patients is the largest 
of IBD mortality published to date. It has shown that in contemporary 
clinical practice IBD patients do have a small increase in mortality 
rate of about 0.5% per annum greater than an age and sex matched 
general population. This excess mortality is not removed by 
correction for confounding by smoking in a multivariate Cox 
regression. Nor is it limited to the initial period after diagnosis of the 
condition since subjects with at least 5 years of disease before entry 
to the study have an only slightly lower hazard than does the entire 
IBD cohort. Overall the hazard associated with Crohns disease (HR 
1.73) is greater than is that of Ulcerative colitis (HR 1.44). The effect 
of the excess mortality in terms of life expectancy (uncorrected for 
any confounding) is to reduce this by 3.5 years in IBD patients (2.3 
in UC and 5 in Crohns disease).  
 
This study is the first to compare IBD patients to both a healthy and 
a general population. After exclusion of subjects with a history of 
malignancy or of a number of common chronic diseases associated 
with increased mortality we have demonstrated a hazard ratio of 
around 2 for death among IBD patients. The size of this study also 
allows examination of the effect of age in greater detail than has 
previously been possible, and in this respect it is important to note 
that although the hazard ratios are greatest for these diseases 
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among young people, the absolute risk difference is higher among 
older age groups.  
 
Aside from the benefits that it derives from greater power, and the 
correction of confounding by smoking, our study has some other 
advantages. Firstly it is likely to better represent the national (as 
opposed to regional or even centre based) mortality experience of 
IBD patients than are previous studies, which have been limited to 
specific areas within a nation. Also because in contrast to most 
other population based studies we have included both prevalent and 
incident cases it is better able to reflect the mortality due to late 
complications of IBD (such as malignancy) than are previous 
studies. Finally since our study is based upon data purely from 1987 
to 2001 it is more representative of current rather than historical 
levels of risk, which is of importance in view of the fall in mortality 
certified as caused by IBD over recent decades71 despite the rise in 
incidence of these diseases. 
 
There are however some limitations to our study. Firstly we were 
unable to individually validate the diagnoses of all the cases.  
Nonetheless the diagnosis of IBD has previously been validated 
within the GPRD and been found to be valid in over 90% of cases77.  
Furthermore when we limited our analyses to cases with at least two 
coded episodes of IBD (for whom greater validity might be 
expected) we did not see appreciable changes in the hazard ratios 
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calculated. The other side of this problem is of course that since IBD 
may remain quiescent for long periods it is likely that some cases 
will not have been recorded by their GPs during the time window of 
our data. It has been shown by validation studies utilising hospital 
letters that the vast majority of diagnoses relevant to hospital care 
are recorded in GPRD 70, 76, and hence we can expect to have 
detected patients under follow-up. Any non-recording therefore may 
be greatest among those with inactive disease who are not under 
hospital follow-up. The results therefore may be generalisable to 
those under follow-up for IBD rather than to all individuals who have 
ever received a diagnosis of IBD.  
 
Secondly there may be a chance that control deaths might be 
underreported if controls are more likely than cases to move without 
informing their GP (a chronic disease might well keep one in greater 
touch with ones doctor).  Such under-reporting might be suggested 
by the fact that controls appeared based on the SMR results to have 
lower than expected mortality, although this cannot directly address 
the question of whether it is differential between cases and controls. 
Against this when we excluded subjects with no events recorded in 
their last year of data there was little change and so this potential 
bias is unlikely to be important. In fact it may even be that the low 
SMR of the controls is an indication that IBD patients come from a 
section of the population at lower than average risk of death. (This 
could easily be so if for example those sleeping rough who are 
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unlikely to register for healthcare in the normal way do not contribute 
cases since they are at markedly increased risk of death.)  
 
The data on confounders such as smoking is clearly incomplete. It is 
possible that this has resulted in some uncorrected residual 
confounding, but this should be considerably less than in previous 
studies without data on these factors. It is also important to note that 
there is potential for bias with respect to which subjects have 
missing data (which has been shown to occur in a validation of 
smoking data within GPRD73), our analysis strategy by including a 
category for missing data rather than ignoring affected subjects will 
have minimised the potential influence of this. To investigate 
whether this was a problem specifically with respect to smoking we 
carried out an analysis limited to current smokers (for whom there is 
reason to believe the data is most valid73) and found that this did not 
greatly alter our results. As for all studies of this type since cases 
present preferentially when they are most unwell, and therefore at 
greatest risk of death, the earliest part of the follow up may carry a 
higher risk of death. In contrast to most other studies we have been 
able to demonstrate that this effect though real is not great since the 
censoring of the first year of follow up only slightly reduces the 
hazard ratios found.  
 
The use of prevalent as well as incident cases within the study has 
potential to cause bias since those prevalent subjects not detected 
  
 131
and therefore not included may differ from those who are included. 
Within this dataset since patients do not in general choose a GP for 
reasons related to illness, this is most likely to occur if those 
susceptible to death due to IBD die early in the course of their 
disease (leading to a bias towards a healthier cohort), or if those 
with mild or quiescent disease among the prevalent cases cease to 
consult their GP and are therefore at increased chance of being 
missed (leading to a bias towards a less healthy cohort). The 
analyses restricted to incident cases and to prevalent cases show 
that there is some difference between the mortality experienced by 
these groups with incident cases experiencing in general greater 
mortality for CD and lower for UC, however the confidence intervals 
for these restricted analyses do not exclude the findings from the 
total cohort.  
 
Finally we should note that in the life table analysis there is no 
correction made for the confounding factors addressed in the Cox 
regression. This clearly implies that we should not attribute the 
whole of the 5-year reduction in life expectancy seen in Crohns 
disease to the disease itself since at least a part of this can be 
expected to be due to smoking. Equally however one might argue 
that this method will underestimate the impact of UC on mortality 
and hence it is likely that the true reduction in life expectancy due to 
IBD does indeed lie somewhere between the figures for UC and 
Crohns. This difficulty is an inevitable consequence of such a life 
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table analysis. Such analysis although it must be interpreted with 
some care has however we believe value in the communication of 
results to non-epidemiologists. This belief is due to the fact that 
during the review process for a paper produced from this study87 it 
became clear that much of the likely readership might have difficulty 
interpreting the magnitude of the results presented in the form of 
harazrad ratios. In particular it seemed that they might overestimate 
the likely effect of IBD upon life expectancy. 
 
Our results are consistent with some other population based studies 
of IBD mortality reported in the last decade which have shown 
SMRs from 1.3 to 1.6 for CD43, 47 and of 1.4 for UC42, 43  although 
these studies included data from as early as the early 1960s. Other 
studies from Britain39, 88 and Italy44, 46 based upon more recent data 
have failed to demonstrate any significant excess mortality. The 
studies finding no excess mortality have in general however been 
small (none of the cited examples containing more than 100 
deaths), and have also been largely limited to the early years of 
incident disease. Among the differences between our results and 
those of previous studies of particular interest is the fact that hazard 
ratios for death for UC are greater among those with a long disease 
history (at least five years of disease). This is in contrast to the early 
descriptions of UC mortality in which this was greatest in the early 
period,89 and may well reflect improved acute disease management 
over the years allowing patients to survive to experience the longer-
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term risks of the disease such as malignancy. It is equally notable 
that for Crohns disease the mortality hazard does not rise with 
prolonged disease as was once the case90 perhaps suggesting 
improved long term management. 
 
In summary our study suggests that there is a 54% excess mortality 
associated with a diagnosis of IBD. In relative terms this effect is 
most marked in the young.  Although this excess is smaller than that 
associated with smoking within our study (96% excess for current 
versus never smokers) it is an important excess being comparable 
to the excess associated with male sex (41%) or that reported in the 
UK for manual versus non-manual occupations in the UK (48% 
excess)91.
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Chapter 7. The risk of fracture in patients with IBD. 
7.1. Introduction 
This chapter will describe a study of the risk of hip fracture in IBD 
and the role of steroid use within this using the cohorts described in 
Chapter 5. 
 
7.2. Methods 
7.2.1. Identifying fractures. 
For each subject we used a combination of Oxmis and Read coding 
to assess whether they had experienced a hip fracture Table IV-30 
and when this had occurred. For each individual only the first 
recorded hip fracture was considered.  The identification of all 
fractures was conducted in like manner using the codes listed in  
Table IV-31.  
 
7.2.2. Corticosteroid use 
We extracted data on the use of systemic corticosteroids from the 
therapy files of our subjects. All prescriptions for systemic 
corticosteroids (excluding topical and inhaled use) were extracted, 
and based upon their dates a subjects time within the study was 
divided into that during which the subject was considered a current 
user (within 90 days of a corticosteroid prescription) and that when 
they were not. (This can be thought of as modelling a reversible 
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component of the risk of corticosteroid use). For each of these time 
periods the incremental total corticosteroid use (as number of 
prescriptions to that point in time) was calculated. (This can be 
similarly thought of as modelling an irreversible risk due to 
corticosteroid use).  Since only the first fracture is considered in our 
analysis, a fracture causes exit from the study. Hence analysis of 
hip fractures, and all fractures are based upon slightly different time 
periods. To avoid undue duplication only the results for steroid use 
relevant to the hip fracture study are presented. 
 
7.2.3. Other drug use and falls. 
We also extracted data on the use of the use of corticosteroids, 
opioid analgesics, hormone replacement therapy (HRT), 
bisphosphonates, calcium and vitamin D supplements and the 
frequency of falls. The use of these drugs was coded as 
prescriptions occurring never, less than once a year or more than 
once a year: falls were coded in like manner based on frequency of 
diagnostic/symptom coding for falls (Table IV-29). 
 
7.2.4. Statistical analysis 
For all analyses in this study as in the study of mortality time was 
calculated from the date of the first prospectively recorded IBD code 
(the matched cases relevant date was used for controls). Univariate 
analysis of fractures using the matched cohort design was 
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conducted by the production of crude fracture rates. Multivariate 
analyses were conducted using a Cox regression model, and the 
validity of the assumption of proportional hazards was assessed 
using Log Log plots and Statas own diagnostic test. As age and sex 
are known to be associated with both the risk of IBD and the risk of 
hip fracture they were included within our models on an a priori 
basis. Other potential confounding factors added to this base model 
were retained only if they resulted in a 10% or greater change in the 
hazard ratio for IBD. For blood pressure and smoking the 
confounding variable was included in the analysis as a categorical 
variable with a category representing missing data. Although low 
BMI is known to be associated with fracture risk and is associated 
with IBD it was not considered as a confounder since it is likely to be 
on the causal pathway between IBD and fracture risk and hence to 
do so would be inappropriate. The multivariate analyses were 
repeated stratifying for disease. Tests for interaction between 
identified risk factors were carried out. In addition restriction 
analyses were carried out to examine the risks among those who 
were incident cases of IBD. Finally we repeated our analyses for all 
fractures to asses the specificity of any association to hip fractures. 
 
All analyses were conducted using Stata version 7 (Stata 
Corporation, College Station, Texas 77845 USA).
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7.3. Results 
7.3.1. Use of corticosteroids 
Table 7-1 shows the use of corticosteroids among groups of IBD 
patients and among their controls. Corticosteroids prescriptions 
occurred more often for the IBD cases (32% received 1 or more 
prescriptions per year compared to only 2% of controls), and they 
had received more such prescriptions in total (22% received more 
than 5 compared to only 1% of controls). 
 
7.3.2. The use of other drugs 
The use of opioid analgesics, hormone replacement therapy (HRT), 
bisphosphonates and calcium and vitamin D supplements in IBD 
patients and controls both overall and by disease type is presented 
as a frequency of prescriptions per year in Table 7-2. Opioid use 
was more common among all groups of IBD patients than among 
their controls. Few subjects received HRT, bisphosphonates or 
calcium and vitamin D supplements, and this remained true among 
those experiencing a hip fracture. Of these only 27 (9%) of 295 
received one or more of these medications at any time. 
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 All IBD UC Crohns Indeterminate 
  % cases % controls % cases % controls % cases % controls % cases % controls
Corticosteroid 
prescriptions  
(total number)         
 0 51 93 53 93 46 94 60 93 
 1-5 27 5 28 5 28 5 21 6 
 6-15 13 1 13 1 15 1 11 1 
 16-25 4 0 3 0 5 0 4 0 
 >25 5 0 3 0 6 0 4 0 
             
Corticosteroid 
prescriptions 
(Density per year)            
 0 51 93 53 93 46 94 60 93 
 Under 1 17 5 18 5 17 5 13 5 
 1 or more 32 2 29 2 38 2 27 2 
 
Table 7-1 Corticosteroid prescriptions in cases and controls. 
Presented both by frequency and total count and divided by type of IBD.
  
 139
 All IBD UC Crohns Indeterminate 
  % cases
% 
controls % cases
% 
controls % cases 
% 
controls % cases
% 
controls
Opioid analgesics            
 0 75 94 78 94 70 94 75 93 
 Under 1 13 4 12 4 13 4 14 5 
 1 or more 12 2 10 2 17 2 12 2 
Calcium and Vit D            
 0 96 99 97 99 94 99 96 99 
 Under 1 2 0 2 0 3 0 1 1 
 1 or more 2 1 1 1 3 1 2 1 
HRT            
 0 92 94 93 94 92 94 91 94 
 Under 1 2 2 2 2 2 2 3 2 
 1 or more 6 4 5 5 6 4 6 4 
Bisphosphonates            
 0 98 99 98 99 98 99 98 99 
 Under 1 1 0 1 0 1 0 1 0 
 1 or more 1 0 1 0 1 0 1 0 
Table 7-2 Prescription frequency of Opioids, HRT, Bisphosphonates and calcium and vitamin D supplements in cases and controls.
  
 140
7.3.3. Univariate analysis of hip fractures 
The IBD cohort contributed 61,130 years of follow up and 72 hip 
fractures and controls 306,082 years of follow up and 223 hip 
fractures. These corresponded to crude hip fracture rates of 11.8 
per ten thousand person years for cases and 7.3 per ten thousand 
patient years for controls. A breakdown of hip fractures, follow up 
available and crude rates by disease type and sex is given in Table 
7-3 and by age and sex is given in Figure 7-1. Expressing these 
results as hazard ratios via a univariate Cox regression model 
showed hazard ratios of 1.62 (95% CI 1.24-2.11) for all IBD, 1.49 
(95% CI 1.04-2.15) for UC, 2.08 (95% CI 1.36-3.18) for CD, and 
0.85 (95% CI 0.30-2.47) for indeterminate IBD compared to their 
respective controls. Log-log plots showed no gross violation of the 
proportional hazards assumptions in these models: an example is 
shown in Figure 7-2. 
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  Controls  Cases 
IBD type sex 
Hip 
fractures 
Follow up 
(years/10000)
Hip fracture rate
/10000 years 
95 % CI  
Hip 
fractures
Follow up 
(years/10000)
Hip fracture rate
/10000 years 
95 % CI
            
All Female 172 16.38 10.50 9.05 12.20  58 3.26 17.81 13.77 23.04
 Male 51 14.23 3.58 2.72 4.72  14 2.86 4.90 2.90 8.28
             
Indeterminate Female 19 2.44 7.78 4.96 12.20  4 0.49 8.10 3.04 21.57
 Male 4 1.78 2.25 0.85 6.00  0 0.36 0.00 . . 
             
UC Female 98 7.50 13.06 10.72 15.92  28 1.49 18.74 12.94 27.14
 Male 29 7.98 3.64 2.53 5.23  10 1.61 6.21 3.34 11.55
             
Crohns Female 55 6.43 8.55 6.56 11.14  26 1.27 20.50 13.96 30.10
 Male 18 4.48 4.02 2.53 6.38  4 0.89 4.51 1.69 12.00
 
Table 7-3 Absolute hip-fracture rated by sex and disease group.
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Figure 7-1 Hip fracture rates per 10000 person years by age group. 
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Figure 7-2 Log-log plot of the univariate model of all IBD
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7.3.4. Multivariate analysis of hip fractures 
In the multivariate Cox regression analysis we included age at entry 
to the study and sex as confounders on an a priori basis. There was 
evidence of appreciable confounding in multivariate analyses by 
both current and cumulative corticosteroid use, and by opioid use 
but not by smoking or by any other drug exposure we examined. 
Overall we found a hazard ratio for hip fracture among subjects with 
IBD of 1.42 (95% CI 1.05-1.91) when corrected for age, sex, 
corticosteroid use (both current and cumulative) and opioid use 
Table 7-4. Subdividing IBD cases by disease type showed that after 
correction for confounding the hazard ratio remained greater for 
Crohns disease at 1.68 (95% CI 1.01-2.78) Table 7-6 than for 
ulcerative colitis (1.41 (95% CI 0.94-2.11)) Table 7-5. There was no 
statistically significant evidence of interaction between the effects of 
sex, age, corticosteroid or opioid use and IBD.  Log-log plots for 
these models  as for the univariate ones showed no gross violation 
of the proportional hazards assumptions.  
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 HR 95% CI 
   
Not IBD Case 1.00 . . 
IBD Case 1.42 1.05 -1.91 
   
Female 1.00 . . 
Male 0.42 0.32 -0.55 
   
Age under 40 1.00 . . 
40-59 8.13 2.42 -27.26 
60-79 98.79 31.52 -309.62 
80 or over 461.24 146.26 -1454.53 
   
No steroids 1.00 . . 
1-5 courses 1.30 0.87 -1.96 
6-15 courses 1.06 0.53 -2.10 
16-25 courses 1.99 0.85 -4.67 
Over 25 courses 2.19 0.98 -4.89 
   
No current steroid use 1.00 . . 
Current steroid use 1.35 0.79 -2.32 
   
No opioid use 1.00 . . 
Occasional use 0.62 0.41 -0.96 
Regular opioid use 1.67 1.12 -2.48 
 
Table 7-4 Multivariate analysis of hip fracture risk for all types of IBD 
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 HR 95% CI 
    
Not IBD Case 1.00 . . 
UC Case 1.41 0.94 -2.11 
   
Female 1.00 . . 
Male 0.39 0.27 -0.56 
   
Age under 40 1.00 . . 
40-59 4.93 1.09 -22.25 
60-79 59.14 14.54 -240.48 
80 or over 331.29 80.95 -1355.77 
   
No steroids 1.00 . . 
1-5 courses 1.04 0.57 -1.88 
6-15 courses 1.46 0.64 -3.33 
16-25 courses 1.66 0.45 -6.18 
Over 25 courses 2.77 0.95 -8.09 
   
No current steroid use 1.00 . . 
Current steroid use 1.22 0.58 -2.57 
   
No opioid use 1.00 . . 
Occasional use 0.60 0.34 -1.07 
Regular opioid use 1.37 0.76 -2.48 
 
Table 7-5 Multivariate analysis of hip fracture risk for UC. 
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 HR 95% CI 
   
Not IBD Case 1.00 . . 
CD Case 1.68 1.01 -2.78 
   
Female 1.00 . . 
Male 0.51 0.32 -0.82 
   
Age under 40 1.00 . . 
40-59 13.69 1.73 -108.10 
60-79 150.85 20.88 -1089.82 
80 or over 603.01 82.44 -4410.92 
   
No steroids 1.00 . . 
1-5 courses 1.92 1.05 -3.52 
6-15 courses 0.72 0.19 -2.65 
16-25 courses 2.02 0.57 -7.18 
Over 25 courses 1.11 0.26 -4.78 
   
No current steroid use 1.00 . . 
Current steroid use 1.38 0.59 -3.23 
   
No opioid use 1.00 . . 
Occasional use 0.62 0.30 -1.30 
Regular opioid use 1.88 1.03 -3.43 
 
Table 7-6 Multivariate analysis of hip fracture risk for Crohns 
disease 
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7.3.5. Restriction analyses 
When limited to incident cases the hazard ratio for IBD in the 
multivariate model was reduced to 1.30 (95% CI 0.84-2.03). 
However an analysis limited to those among the incident group with 
no record of systemic corticosteroid use but corrected for the other 
elements of the model showed a hazard ratio of 1.80 (95% CI 1.06-
3.08).  
 
7.3.6. Analysis of all fractures 
 
In the analysis using all fractures the level of risk among IBD 
patients was only slightly above that among controls with the 
univariate Cox regression giving a hazard ratio for all IBD of 1.14 
(1.06-1.24). The hazard was slightly higher for UC (1.16 (1.04-1.30)) 
and lower for Crohns disease (1.11 (0.97-1.28)). In the multivariate 
analysis these hazards were attenuated by correction of 
confounding and ceased to differ significantly from unity Table 7-7, 
Table 7-8, Table 7-9.
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 HR 95% CI 
    
Not IBD Case 1 . . 
IBD Case 1.03 0.94 1.14 
    
Female 1 . . 
Male 0.92 0.86 0.98 
    
Age under 40 1 . . 
40-59 0.90 0.83 0.98 
60-79 1.56 1.44 1.69 
80 or over 3.73 3.32 4.20 
    
No steroids 1 . . 
1-5 courses 1.27 1.12 1.45 
6-15 courses 1.29 1.05 1.59 
16-25 courses 1.30 0.92 1.82 
Over 25 courses 1.46 1.04 2.04 
    
No current steroid use 1 . . 
Current steroid use 1.36 1.14 1.61 
    
No opioid use 1 . . 
Occasional use 0.52 0.45 0.61 
Regular opioid use 1.12 0.97 1.31 
 
Table 7-7 Multivariate analysis of all fractures in all cases and 
controls
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 HR 95% CI 
    
Not IBD Case 1 . . 
UC Case 1.15 0.91 1.45 
    
Female 1 . . 
Male 0.93 0.78 1.10 
    
Age under 40 1 . . 
40-59 0.62 0.50 0.78 
60-79 1.32 1.08 1.62 
80 or over 2.55 1.85 3.50 
    
No steroids 1 . . 
1-5 courses 0.81 0.55 1.20 
6-15 courses 0.99 0.56 1.76 
16-25 courses 1.31 0.57 3.01 
Over 25 courses 0.68 0.23 2.04 
    
No current steroid use 1 . . 
Current steroid use 2.12 1.29 3.47 
    
No opioid use 1 . . 
Occasional use 0.58 0.40 0.82 
Regular opioid use 1.15 0.77 1.71 
 
Table 7-8 Multivariate analysis of all fractures in UC 
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 HR 95% CI 
    
Not IBD Case 1 . . 
CD Case 0.94 0.80 1.12 
    
Female 1 . . 
Male 1.05 0.95 1.17 
    
Age under 40 1 . . 
40-59 0.98 0.85 1.12 
60-79 1.81 1.59 2.06 
80 or over 3.37 2.73 4.16 
    
No steroids 1 . . 
1-5 courses 1.58 1.29 1.94 
6-15 courses 1.39 0.98 1.98 
16-25 courses 1.32 0.76 2.29 
Over 25 courses 1.50 0.87 2.59 
    
No current steroid use 1 . . 
Current steroid use 1.14 0.86 1.51 
    
No opioid use 1 . . 
Occasional use 0.45 0.35 0.59 
Regular opioid use 1.14 0.90 1.46 
 
Table 7-9 Multivariate analysis of all fractures in Crohns disease 
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7.4. Discussion 
 
We have shown that in this general population based cohort study 
the rate of hip fracture among patients with IBD is some 60% higher 
than that of their matched controls. This increase is greater in 
Crohn's disease in which there is a 2 fold increase in risk than in UC 
where it is 1.5 fold. These findings are in contrast to the only 
previous European cohort study, which reported only a non-
significant excess of about 10% for both diseases 58, but are not 
dissimilar to those reported by a large North American study which 
found a 47% excess in CD patients and a 69% excess in UC 
patients 56.  In multivariate analyses these relative risks are reduced 
by correction for age, sex, current steroid use, cumulative steroid 
use and opioid use. After correction for these factors an increase in 
risk of 42% for IBD overall, 41% for UC and 68% for Crohns 
disease remained. Within our multivariate model current use of 
steroids was associated with a reversible 35% increase in the risk of 
hip fracture, and the receipt of on average one or more prescriptions 
for opioid analgesics each year with a 67% increase in risk. 
Irrespective of all other factors hip fracture in our study remains very 
rare under 60 years of age both among those with and without IBD, 
and even over the age of 60 is far more common among females. 
 
In this analysis we looked primarily at the risk of hip fracture for 2 
reasons. Firstly this is a very suitable outcome to study when 
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attempting to assess the impact of osteoporosis upon the health of 
IBD patients, since hip fracture is clearly related to osteoporosis, 
and is associated with significant morbidity and mortality92, 93. 
Secondly since hip fractures will in general result in hospitalisation 
and correspondence, they will be less susceptible to the 
ascertainment bias that might occur with other fracture types if (as 
for both BMI and smoking behaviour) their recording were more 
complete for the IBD cohort than for healthy controls. It is possible 
that some fractures that do occur go unrecorded, and also that 
some diagnoses of fractures or, of IBD may be in error. Such error 
would be likely to be random and hence lead to an underestimate in 
the risk we have shown, but is unlikely to be a major problem since 
both hip fracture recording94 and IBD diagnosis77 within GPRD have 
been independently validated and found to be accurate in over 90% 
of cases. One disadvantage of the choice of hip fracture is that since 
this is a fracture predominantly of the elderly and IBD has its peak 
incidence in young adulthood, there is potential for the disease or its 
therapy to have had a predisposing effect prior to the period 
observed. These points must be born in mind when interpreting the 
results of our analysis of all fractures. Despite them the absence of 
an excess similar to that seen for hip fracture, (since ascertainment 
bias would be expected to increase the excess) supports the 
arguement that there is some degree of specificity with respect to 
fracture site. This in turn might suggest that the effect upon hip 
fracture is via weakening of bone rather than increase in trauma, but 
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such an interpretation should be made with caution as the data 
would be equally compatible with an increase in low impact injury 
(causing fracture in those susceptible) accompanied by a reduction 
in high impact injury (which might occur if for example IBD patients 
were less likely than average to take part in dangerous sports). 
 
Our finding that corticosteroid use is a confounder of the increased 
hip fracture risk we have seen is consistent with previous studies. 
Corticosteroids are commonly used to treat IBD, and are known to 
be associated with increased risk of fracture95. Further they have 
previously been shown repeatedly to be confounders of the 
association with osteoporosis in IBD51-53, 96, and in the only previous 
study to examine their role in it of fracture risk in IBD57.  This latter 
study however was reliant upon a self-administered questionnaire 
for data relating to steroid use, which introduced the potential for 
recall bias. Our study by using prospectively gathered prescription 
data avoids this problem. We have also been able to look not only at 
the effect of cumulative use as was previously attempted, but also at 
the effect of current use which has recently been suggested as an 
important risk factor for fracture65, and previously been shown to 
predict reduced bone density in Crohns disease96. That there is 
significant risk associated with IBD after correction for available 
confounders including corticosteroids suggests however that they 
are not a complete explanation of the risk. . Our findings suggest 
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that they can account for less than half of the excess fracture risk in 
Crohns and less than 20% of that in UC. 
 
It is important to recognise the limitations to precise estimation of 
steroid exposure in our subjects. For the nearly 60% who were 
prevalent cases the GPRD will not have captured exposure prior to 
entry into the database. In addition some exposure to steroids will 
be prescribed by hospitals and therefore not captured. It is for this 
reason that our estimates of cumulative exposure are in broad 
categories, allocation to which should remain valid despite these 
limitations. The imprecision of our estimates of cumulative steroid 
use however means that it is possible that there is residual 
confounding from them, and that hence we may have 
underestimated the role of corticosteroids. The subgroup analyses 
of all incident cases, and of incident cases with no record of steroid 
use that we have conducted allow us to some extent to assess the 
importance of these limitations. Although these analyses are 
inevitably of very limited power, that they show increased risk in 
groups free from these problems suggests that their impact may not 
be great. These findings are consistent with the previous 
observation that CD patients have reduced bone mineral density at 
diagnosis61. 
 
Although we have found that hip fracture is associated with both 
current and cumulative corticosteroid use in IBD this does not prove 
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that corticosteroids cause the increased risk seen. It is equally 
possible that corticosteroid use is a marker of increased 
inflammatory activity (since they will be given when such activity 
occurs) and that this directly affects bone metabolism97. A further 
possibility is that the risk is at least in Crohns disease related to 
bowel malfunction and the recent finding of a similar excess of hip 
fracture risk in persons with coeliac disease98 might support this 
idea.  
 
Our other important findings are of an increased risk of hip fracture 
in IBD patients using opioids regularly, which confounds the risk 
associated with IBD, and a low rate of use of bone protecting 
medications. Since an excess risk of fracture in opioid users has 
previously been shown99, and there is evidence to suggest that 
dependence upon them is not rare in IBD100 it is unsurprising that 
they should be confounders in this context. It is perhaps no more 
surprising since the prevention of osteoporosis has only relatively 
recently gained prominence in the literature that we found little use 
of medications aimed at doing so in this dataset collected between 
1987 and 2001. This finding does however point up the opportunity 
for prevention that may be present.  
 
In conclusion we have found that IBD is associated with a roughly 
60% increase in risk of hip fracture. We have also found that 
although corticosteroids might explain some of this risk, they 
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certainly cannot explain it all, and probably explain rather less than 
half of it even in Crohns disease where they have their greatest 
effect. The finding that corticosteroids have an effect not only 
through prolonged consumption, but also a rapid and reversible 
effect supports the suggestion that prophylactic therapy should be 
initiated acutely with corticosteroids101, 102.  Finally our findings 
suggest that although the majority of the excess hip fracture risk in 
IBD may not be due to drug use, there is an opportunity to reduce 
this risk by reducing the use of opiates and increasing the use of 
prophylactic medication. 
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Chapter 8. Conclusions 
8.1. Main findings 
 
The studies presented in this thesis fall into two groups which are 
most easily discussed separately.  
 
The first two studies examined hypotheses regarding the aetiology 
of IBD, and the possibility that this is linked to relationship between 
the gut and microorganisms. Within this vast area of research we 
have been able to add to knowledge in two small ways. Firstly we 
have added a further study to the literature relating to the role of 
season of birth as a risk factor for Crohns disease. Our study 
showed no evidence of such a role. Secondly we have conducted 
the first study specifically designed to examine the possibility that 
antibiotic use might predispose to or precipitate Crohns disease. 
This study found a clear association between antibiotic use and 
subsequent diagnosis of Crohns disease 2 to 5 years later but since 
similar associations existed for other drug groups the association is 
likely not to be causal. 
 
The other two studies presented look at the impact of IBD. We have 
looked not at the direct symptomatic effects of IBD but rather at 
some serious adverse consequences that may in some cases be 
attributable only indirectly if at all to the disease. The first of these 
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studies demonstrated a roughly 50% increase in risk of death 
among IBD patients after correcting for the confounding effects of 
smoking. This corresponded to a roughly 3.5 yr loss in life 
expectancy overall. The risk was greater in Crohns disease than in 
UC, and was greater in absolute terms in the elderly but in relative 
terms in the young. The second of these studies examined the risk 
of fracture (and in particular of hip fracture) in IBD and attempted to 
elucidate the contribution of corticosteroid therapy to this. This study 
demonstrated a roughly 1.6 fold increase in hip fracture risk in IBD 
patients which was higher among CD patients (2.1 fold) than UC 
patients (1.5 fold). These effects were not found when all fractures 
were analysed, and were in part explained by corticosteroid use 
(both long and short term) and by opiate analgesic use since the 
inclusion of these three exposures within a multivariate model 
attenuated the hazard ratios seen. 
 
 
8.2. Suggestions for further research  
A discussion of potential future epidemiological research into IBD 
covering all aspects of the investigation of its aetiology and impact is 
clearly beyond the scope of this thesis. I shall therefore restrict 
myself to future research which arises fairly directly from the studies 
presented above.  
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8.2.1. Month of birth and the risk of IBD. 
For the reasons outlined in the discussion of Chapter 2 it is unlikely 
that any very similar study to that which we undertook will yield 
useful results in the UK. It is perhaps unwise to suggest that 
seasonality will not more easily be found elsewhere however in view 
of the clear geographic variation in the results of similar studies into 
type 1 Diabetes31, and the recent emergence of a rational which 
might well explain this103.  
 
8.2.2. Antibiotic use and the risk of Crohns disease. 
 
The paucity of previous examination of the possibility that antibiotics 
have played a role in the rise in Crohns disease, along with the 
limitations of the study presented in Chapter 4 mean that there is 
clear potential for further research in this area. Many different 
studies in this area might be proposed including the repetition of our 
examination of the effect of antibiotics over a small number of years 
(since there is always the need to repeat observational studies 
before accepting their results). One approach with great potential 
advantages that could examine a subtly different hypothesis would 
be a case control study measuring, as its primary exposure 
antibiotic use from birth onwards assessed via contemporaneous 
medical records, and assessing a variety of other potential 
confounders both from records and questionnaires. Such a study 
would have the same advantage of avoiding recall bias which we 
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were able to achieve, but would in addition be able to gain rather 
better data on potential confounders than we could and to examine 
the possibility that the exposures effect is limited to a particular 
point in the life course. Such an age specific effect in early life would 
to some extent mirror the hygiene hypothesis which has been 
previously investigated12, 13 as well as tying in with the suggestion 
that caesarian sections or other perinatal events might affect the risk 
of Crohns disease104.  It would also mirror the age specific effect of 
antibiotics that has been described in relation to the risk of asthma 
and allergy105, 106. 
 
8.2.3. Mortality in Inflammatory Bowel Disease 
 
The need for ongoing study of the mortality associated with 
inflammatory bowel disease is illustrated beautifully by the recent 
publication of results radically different to those that we have 
presented from a well-conducted study in Denmark107, 108. This was 
a study of an incident cohort and calculated the relative risk of death 
as an SMR with the Danish general population figures being used 
as the comparator which found no excess in risk. Some of the 
potential reasons for the discrepancy between these results point to 
useful areas of future research. It is likely that one reason that we 
found a far higher level of mortality is that our case selection will be 
likely to have excluded those who were quiescent throughout their 
GPRD record. Although at one level it is easily understandable that 
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sick people die more than well ones, the greater elucidation of 
precisely which patients with IBD are at increased risk of death 
would be of obvious benefit. Another likely reason for the 
discrepancy is the differences in choice of control populations 
between studies. It is generally assumed that where a population 
based incident cohort is the case population it is reasonable to 
compare this to mortality figures for the general population as a 
comparator. The low SMR of our control population must suggest 
however either an incomplete recording of death in the GPRD 
(which could not explain the difference between our results and 
those from Denmark unless it were differential), or that IBD patients 
are drawn from a subset of the population with below average 
mortality. The latter explanation would be far from surprising if we 
consider that the ascertainment of IBD but not of death is likely to be 
poor among those with poor access to health care (such as the 
homeless). It would also fit well with existing evidence that IBD is 
commoner among those living in more affluent settings. Clearly the 
examination of this question in other cohorts is of great potential 
methodological consequence. 
 
8.2.4. The risk of fracture in patients with IBD. 
 
One of the great unanswered questions regarding IBD and bone 
disease is whether the observed association between 
corticosteroids and bone disease in this setting reflects a primary 
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effect of the corticosteroids or an effect of the disease activity which 
they are treating. This is a problem that will be extremely difficult to 
disentangle in adult IBD patients by observational means. A 
potentially useful methodology for the partial examination of this 
problem may be a randomised controlled clinical trial comparing 
steroids and elemental diet in the treatment of Crohns disease. 
Although this could not reasonably provide power to examine 
fracture risk it would permit the evaluation of short-term changes in 
bone density, whether they were steroid dependant or not and over 
what time period if at all they were reversible. If steroids are 
responsible for the acute reversible increase in fracture risk which 
we have described then one would expect them to be associated 
with a marked and reversible reduction in bone density which did not 
occur in the diet arm of the trial. 
 
8.3. Conclusion 
 
The accumulating evidence that disordered relationships between 
the gut and its flora may be involved in the aetiology of IBD gave 
rise to two hypothesese which we were able to investigate. Although 
we found no evidence in support of a risk related to the season of 
birth and a possibly non-causal relationship with the use of 
antibioitics this area of research remains one of great interest.  Our 
investigation of the risks of death and of hip fracture gave rise to 
more clearly conclusive results than did our aetiological studies. We 
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demonstrated a clear increase in risk of both of these outcomes that 
was greater in Crohns disease than in UC. There remain however a 
number of outstanding questions related to these results both in 
terms of methodology and of the precise causation of these risks.
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Appendix I. Source data for live births 
This appendix presents source data for live births registered 
between 1978 and 1998 that has been compiled to give live births 
from 1978 to 1998 for the whole of the UK. 
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  January February March April May June July August September October November December
              
1978  46.6 44.3 51.5 48.8 51.1 49.4 50.6 51.3 52.7 51.6 48.4 50.2 
1979  51.4 48.6 56.2 53.4 56.8 54.5 55.6 53.7 52.9 53.7 50.8 50.5 
1980  54.4 51.5 56.4 55.5 57.8 54.7 57.9 54.8 55.6 55.4 50.5 51.6 
1981  52.7 48.5 55.0 52.8 54.7 53.4 56.5 54.2 53.6 53.2 49.9 50.0 
1982  51.5 47.7 54.3 52.2 53.8 51.0 54.5 53.4 54.2 53.0 49.4 51.0 
1983  51.2 47.6 53.6 52.6 54.8 54.0 55.4 53.8 54.3 51.5 49.7 50.7 
1984  51.3 48.9 53.3 50.1 54.3 53.4 55.9 55.8 55.4 55.3 52.5 50.6 
1985  54.7 49.6 56.0 53.3 57.5 54.5 58.2 57.1 57.0 55.8 51.9 50.7 
1986  53.6 49.6 56.7 55.2 58.2 55.7 56.7 57.4 56.7 55.9 51.1 54.2 
1987  54.6 50.6 57.6 56.3 59.8 58.9 59.8 58.1 58.7 57.8 53.6 55.9 
1988  57.3 55.2 60.8 58.0 60.4 58.1 60.2 59.6 59.3 55.5 53.6 55.5 
1989  55.8 52.3 58.9 56.9 60.7 59.1 60.1 58.9 56.8 56.8 55.0 56.4 
1990  56.5 52.9 58.9 57.2 61.4 60.7 62.5 61.2 60.3 59.9 57.6 57.1 
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1991  58.8 54.1 58.5 56.7 60.1 59.0 62.0 60.4 59.4 58.7 55.3 56.2 
1992  58.3 55.6 58.8 57.6 59.4 58.6 61.0 58.8 58.3 56.4 53.3 53.5 
1993  55.4 50.7 56.3 54.8 57.6 57.7 59.0 57.8 59.0 56.8 52.6 55.8 
1994  55.4 51.0 57.9 55.4 58.1 57.1 57.3 55.5 56.1 55.5 52.2 53.1 
1995  53.5 49.7 55.4 52.2 56.7 55.8 56.5 55.6 55.3 54.9 51.4 51.2 
1996  53.5 50.4 53.4 50.5 53.8 53.7 57.6 56.0 56.4 56.2 53.8 54.2 
1997  54.5 49.5 54.1 54.0 55.4 53.9 56.4 54.8 53.7 53.0 50.7 53.1 
1998  53.4 48.8 53.6 52.4 53.0 53.1 56.4 54.4 55.3 53.6 50.1 51.6 
Table I-1  Numbers of live births in England and Wales by month from 1978-98 
  
 168
 
  January February March April May June July August September October November December
              
1978  5,262 4,902 5,611 4,852 5,555 5,429 5,283 5,681 5,378 6,027 5,277 5,038 
1979  5,897 4,996 5,816 5,725 6,010 5,666 6,058 5,982 5,085 6,253 5,556 5,322 
1980  5,724 5,476 5,510 5,973 5,868 5,635 6,019 5,605 5,633 6,280 5,172 5,997 
1981  6,052 5,333 6,150 5,739 5,610 5,767 5,929 5,745 5,573 6,119 5,446 5,591 
1982  5,472 5,106 5,997 5,658 5,239 5,366 5,549 5,693 5,462 5,908 5,437 5,309 
1983  5,499 4,964 5,631 5,227 5,370 5,693 5,498 5,873 5,512 5,633 5,128 5,050 
1984  5,383 4,937 5,347 5,154 5,448 5,316 5,798 5,853 5,200 6,158 5,453 5,059 
1985  5,683 4,993 5,287 5,786 5,615 5,185 6,034 5,788 5,415 6,323 5,227 5,340 
1986  5,578 4,859 5,086 6,000 5,592 5,566 5,723 5,339 5,563 5,947 5,003 5,556 
1987  5,540 5,019 5,529 5,462 5,364 5,899 5,955 5,540 5,525 5,883 5,189 5,336 
1988  5,476 5,437 6,006 5,376 5,471 5,697 5,503 5,827 5,513 5,538 5,203 5,165 
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1989  5,525 4,768 5,603 4,973 5,582 5,394 5,326 5,529 5,187 5,588 5,114 4,891 
1990  5,725 4,926 5,496 5,287 5,624 5,430 5,957 5,816 5,160 6,275 5,439 4,838 
1991  5,943 5,069 5,374 5,709 5,645 5,275 6,167 5,735 5,435 6,193 5,198 5,281 
1992  5,886 4,950 5,639 5,529 5,218 5,699 5,966 5,381 5,524 5,634 5,142 5,221 
1993  5,333 4,783 5,660 5,286 5,014 5,327 5,581 5,519 5,368 5,493 5,175 4,798 
1994  5,338 4,692 5,534 5,027 5,188 5,359 5,138 5,336 5,095 5,270 4,984 4,695 
1995  5,313 4,585 5,219 4,626 5,211 5,089 5,057 5,297 4,830 5,429 5,054 4,341 
1996  5,371 4,682 4,476 4,885 4,864 4,491 5,247 5,172 4,703 5,772 4,800 4,833 
1997  5,346 4,581 4,356 5,500 4,942 4,961 5,276 4,890 4,989 5,332 4,372 4,895 
1998  4,924 4,308 4,919 4,807 4,485 4,956 5,085 4,800 4,911 5,081 4,479 4,564 
Table I-2 Live births by month of registration, Scotland 
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  January February March April May June July August September October November December
     
1978   2512 2067 1795 2189 2066 2531 2584 1917 2158 2720 1943 1757 
1979   2783 2070 2267 2647 2436 2291 2674 2176 2293 2483 2275 1783 
1980   2833 2052 2205 2687 2369 2492 2594 2174 2474 2536 2069 2097 
1981   2406 1961 2358 2274 2265 2420 2391 2242 2357 2370 2491 1767 
1982   2353 2278 2235 2152 2529 2366 2389 2442 2212 2562 2275 1900 
1983   2409 2011 2380 2238 2300 2481 2239 2419 2429 2211 2189 1949 
1984   2296 2076 2300 2343 2142 2418 2324 2279 2417 2313 2450 1670 
1985   2603 2099 2226 2431 2446 2221 2520 2236 2447 2440 2164 1802 
1986   2654 2065 2188 2643 2478 2367 2619 2046 2448 2451 2028 2165 
1987   2537 2144 2319 2380 2445 2590 2404 2244 2492 2201 2155 1954 
1988   2494 2248 2421 2313 2523 2356 2342 2508 2291 2277 2262 1732 
1989   2349 2001 2167 2241 2277 2336 2274 2381 2112 2204 2069 1669 
1990   2610 1965 2243 2172 2384 2237 2338 2192 2087 2442 2147 1682 
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1991   2729 1919 2028 2346 2274 2144 2319 2234 2270 2143 2034 1825 
1992   2486 1931 2204 2195 2134 2327 2185 2022 2347 2113 1952 1676 
1993   2191 1846 2209 2129 1938 2309 2118 2065 2178 2034 2130 1762 
1994   2317 1722 2047 2090 1999 2224 1954 2113 2152 2000 1981 1690 
1995   2246 1842 2072 1845 2125 2160 2054 2021 2019 2077 1937 1462 
1996   2510 1875 1829 2084 2041 1854 2122 2127 2101 2268 2041 1730 
1997   2369 1836 1855 2271 1995 2070 2173 1933 2162 2017 1825 1771 
1998   2149 1836 2018 2043 1911 2089 2170 1873 2136 2074 1771 1598 
Table I-3 Births by Month for Northern Ireland 1978-1998 
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Appendix II. The data format of the GPRD 
(Reproduced with permission of The GP Database Research Company 
Limited (EPIC)) 
 
PATIENT RECORDS: 
 
Field Character 
Type 
Max No. Of 
Characters 
Description 
prac 9999 4 Encrypted practice id 
epatid Any ASCII 6 Encrypted patient id 
dob YYYYMM
DD 
8 Date of birth 
sex   9 1 Sex of patient (see note below) 
orgreg YYYYMM
DD 
8 Patients original registration date 
with the practice (derived by 
EPIC) 
regstat   99 2 Registration status (see note 
below) 
xferdate YYYYMM
DD 
8 Transfer out date 
Start_UTS YYYYMM
DD 
8 Patients start of up to standard 
data 
End _UTS YYYYMM
DD 
8 Patients end of up to standard 
data 
 
Note      Patient Records:  
 
 SEX 0   Female 
  1   Male 
 
 REGSTAT 1 Permanent 
  2 Temporary 
  3 Left practice 
  4 Applied for Registration 
  5 Contraception only 
  6 Maternity only 
  7 Private Patient 
  8 Referral 
  9 Inactive 
       13 D=death 
  17 Child Health Survey 
  18 Minor Operations Only 
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MEDICAL RECORDS: 
 
Field Character 
Type 
Max No. Of 
Characters 
Description 
prac 9999 4 Encrypted practice id 
epatid Any ASCII 6 Encrypted patient id 
evntdate YYYYMMD
D 
8 Event date 
medcode Any ASCII  
(case 
sensitive) 
7 OXMIS or Read medical code 
(see MEDCODES) 
rdoxflag A 1 Flag indicating if the code is 
OXMIS or Read (see note below) 
outcome A 1 Outcome (see note below) 
mclinspe AAA 3 Clinical speciality (see note 
below) 
textid 9999999 7 Identifier used to locate a 100 
character text comment in the 
VMTEXT file. These comments 
are confidential (see note below) 
 
Note              Medical Records: 
 
       RDOXFLAG O OXMIS code in medcode field 
  R Read code in medcode field 
  U Unmatched record  deletion on 
collection that could not be matched to 
original record 
  C Read code record which was originally 
in OXMIS and has been amended 
since practice moved to read 
 
 OUTCOME A Inpatient, Doctor referral to Accident 
& Emergency 
  C Outpatient, Self referral to Accident & 
Emergency 
  D Inpatient, hospital discharge summary 
  E Outpatient, Doctor referral to Accident 
& Emergency 
  H Inpatient, hospital admission 
  L Hospital letter 
  M Minor Surgery 
  O Other 
  R Outpatient referral 
  S Inpatient, Self referral to Accident & 
Emergency 
 
 MCLINSPE DER Dermatology 
  ENT Ear Nose & Throat 
  GER Geriatrics 
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  GYN Gynaecology 
  MED General Medical 
  NEU Neurology 
  OBS Obstetrics 
  OPH Ophthalmology 
  ORT Orthopaedic 
  0TH Other 
  PAE Paediatrics 
  PAT Pathology 
  PSY Psychiatry 
  RHE Rheumatology 
  SUR General Surgery 
  XRA X - Ray 
  URI Genito-Urinary 
 
 
VMTEXT  is a file containing the textid and all doctors comments in 
the GPRD. Some of  
these comments can contain confidential information about 
patients so we are unable to give out this file. If you do 
require a comment identifiable by the textid Please contact 
EPIC more further information. 
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THERAPY RECORDS: 
  
Field Character 
Type 
Max No. Of 
Characters 
Description 
prac 9999 4 Encrypted practice id 
epatid Any ASCII 6 Encrypted patient id 
prscdate YYYYMM
DD 
8 Prescription date 
drugcode Any ASCII 8 Encrypted Multilex drug code 
(see GPRDDRUG) 
multflag A 1 Flag to show whether multilex 
or not 
dosage Any ASCII 11 The dosage as entered by doctor 
prscqty 99999 5 Prescription quantity 
prscdays 999 3 Duration of the prescription in 
days 
opno 999 3 Number of original packs 
packsize 99999.99 
(float) 
8       Pack size 
textid 9999999 7 Identifier used to locate a 100 
character text entry in the 
medical records  
dosgval 9999.99  7 The dosage value. Where 
possible the prescribed 
number of units per day has 
been calculated. This 
information together with the 
prescription quantity allows 
the duration of the 
prescription to be calculated. 
 
Note        Therapy Records: 
 
        MULTFLAG Y Multilex code in drugcode field 
  X Undefined PPA code 
  U Unmatched record  deletion on 
collection that could not be matched to 
original record 
  C Multilex code record which was 
originally a PPA and has been 
amended since practice moved to 
Multilex 
 
 
 PRSCTYPE 0  Repeat 
  1  Acute 
   
  
PREVENTION RECORDS: 
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Field Character Type Max No. Of 
Characters 
Description 
prac 9999 4 Encrypted practice id 
epatid Any ASCII 6 Encrypted patient id 
evntdate YYYYMMDD 8 Event date 
prevcode 9999999999 10 Prevention code (see PREVENT) 
prevval1 99999999 8 Prevention value 1 (see 
PREVENT) 
Prevval2 99999999 8 Prevention value 2 (see 
PREVENT) 
medcode Any ASCII  
(case sensitive) 
7 OXMIS or Read medical code 
(see MEDCODES) 
rdoxflag A 1 Flag which indicates if the code 
is OXMIS or Read (see note 
below) 
clinspec AAA 3 Clinical speciality (see note 
below) 
 
Note      Prevention Records: 
 
        RDOXFLAG O OXMIS code in medcode field 
  R Read code in medcode field 
  U Unmatched record  deletion on 
collection that could not be matched to 
original record 
  C Read code record which was originally 
in OXMIS and has been amended 
since practice moved to read 
 
  
 CLINSPEC DER Dermatology 
  ENT Ear Nose and Throat 
  GER Geriatrics 
  GYN Gynaecology 
  MED General Medical 
  NEU Neurology 
  OBS Obstetrics 
  OPH Ophthalmology 
  ORT Orthopaedic 
  OTH Other 
  PAE Paediatrics 
  PAT Pathology 
  PSY Pyschiatry 
  RHE Rheumatology 
  SUR General Surgery- 
  URI Genito-Urinary 
  XRA X - ray 
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LOOK UP TABLES  
 
 
MEDCODES: Medical dictionary 
Field Character 
Type 
Max No. Of 
Characters 
Description 
Medcode Any ASCII 
(case 
sensitive) 
7 OXMIS/Read code  
rdoxflag A 
1 OXMIS/Read flag 
Description  Text 
60 Description of the codes  
 
PREVENT: Prevention code information 
Field Character 
Type 
Max No. 
Of 
Characters
Description 
Prevcode 
99999999
99 
10 Prevention code 
Description 
text variable Description of code 
Prevval1 text variable Prevention value 1  
Prevval2 text variable Prevention value 2  
Code Any ASCII 
(case 
sensitive) 
7 Medcode or date 
 
GPRDDRUG: Drug dictionary 
Field Character 
Type 
Max No. Of 
Characters 
Description 
PPAEID 9999999 7 Encrypted PPA code 
MultilexEID Any ASCII 8 Multilex Product and 
Formulation ID encrypted 
BNFCode1 99.99.99.99 11 BNF Hierarchy code 1  
BNFCode2 99.99.99.99 11 BNF Hierarchy code 2 
BNFCode3 99.99.99.99 11 BNF Hierarchy code 3 
GenericName 
Qual  
Text 50 Generic Name and (abbreviated) 
qualifier of the product. 
Formulation Text 50 Formulation  
Strength Text 20 Abbreviated strength (includes 
units)  
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Appendix III.  Papers published from this work 
 
Card TR, Sawczenko A, Sandhu BK, Logan RF. No seasonality in 
month of birth of inflammatory bowel disease cases: a prospective 
population based study of British under 20 year olds. Gut 
2002;51:814-5. 
 
 
Card T, Logan RFA, Rodrigues LC, Wheeler JG. Antibiotic use and 
the development of Crohns Disease. Gut (in press) 
 
Card T, Hubbard R, Logan RFA. Mortality in Inflammatory Bowel 
Disease: a population based cohort study. Gastroenterology 2003 
Dec;125(6):1583-90 
 
Card T, West J, Hubbard R, Logan RFA. Hip fractures in people with 
Inflammatory Bowel Disease and their relationship to corticosteroid 
use: a population based cohort study. Gut (in press) 
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